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ABSTRACT 
Gram-negative bacteria use acyl-homoserine lactone (AHL) based quorum 
sensing (QS) to regulate the expression of genes that give the bacteria a selective 
advantage over host defenses and antibiotic treatment.  Burkholderia mallei is an 
antibiotic resistant pathogen that causes Glanders disease.  B. mallei BmaI1 AHL-
synthase uses octanoyl-Acyl Carrier Protein (C8ACP) and S-adenosyl-L-methionine 
(SAM) to synthesize the AHL, octanoyl-homoserine lactone (C8HSL). Inhibiting AHL-
synthases has been difficult because mechanistic and substrate specificity details for these 
enzymes are not well understood.  Our goal was to determine how BmaI1 activity and 
enzymatic mechanism changes with nonspecific, variable acyl chain acyl-ACP substrates. 
We found that catalytic efficiency of nonspecific acyl-ACP substrates are drastically low 
compared to the native C8ACP substrate, in-line with tight signal specificity observed in 
vivo. In addition, substrates with lower catalytic efficiency also showed kinetic 
cooperativity while reacting with BmaI1. Our results suggest that substrates add by a 
preferred order, random sequential mechanism to BmaI1. Alternatively, BmaI1 could 
exist in two forms, where nonspecific substrates bind to the less active enzyme form and 
leads to the formation of an unproductive E.acyl-ACP complex. Apparently, only the 
native acyl-ACP substrate forms both a stable and productive E.acyl-ACP complex, thus 
providing a molecular basis for substrate discrimination in QS signal synthesis in B. 
mallei. 
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CHAPTER ONE: INTRODUCTION 
Quorum Sensing 
Quorum sensing (QS) is a type of bacterial intercellular communication that 
occurs at high cell population densities.1 QS coordinates bacterial behaviors so as to 
function like a multicellular organism.  The behaviors governed by QS are those that 
when attempted by individual cells are unproductive, however, when attempted by the 
masses provide an evolutionary advantage.2,3  The chemical signal molecules responsible 
for QS are diffusible, low molecular weight (c. 170-300 Da) pheromones referred to as 
autoinducers (AIs).4  QS is achieved through the accumulation of AIs that enable 
individual cells to sense when the minimal population unit or “quorum” of bacteria has 
been achieved for a concerted population response to be initiated.4    
The regulatory components and molecular mechanisms of QS differ among 
bacterial species.  Nonetheless, there are three basic principles that apply to all cases of 
QS.   First, all communicating bacteria produce AIs. When there is a low population 
within a bacterial community, the AIs synthesized are in such low concentration that they 
are unable to stimulate a population-wide response. Once a population reaches high 
density, the cumulative amount of AIs produces a global response. The second principle 
of QS is that receptors for AIs exist in the membrane or in the cytoplasm of the 
responding cells. AIs secreted from one cell bind to neighboring bacteria.  Lastly, AIs 
induce the expression of a variety of genes that can stimulate production of additional AIs 
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through a positive feedback loop to sponsor synchronous behavior in the cell population 
(Fig. 1).5  
 
Figure 1. General scheme of a QS system. The signal synthase enzyme produces 
signal molecules (AIs), which diffuse or are transported to the extracellular environment. 
At an optimal concentration of the signal, the AI binds to the receptor, which can be 
located in the cytoplasm (A) or at the cell surface (B). If the receptor is located in the 
cytoplasm, the AI-receptor complex activates or inactivates the transcription of target 
genes. When the receptor is located at the cell surface, the signal induces a 
phosphorylation signal transduction cascade. This activates a transcriptional regulator 
that leads to targeted gene transcription.5  
QS was discovered 30 years ago in two light-producing bacterial species, Vibrio 
fisheri and Vibrio harveyi.1,2  These bacteria emitted light at high cell population density, 
when the accumulation of secreted AIs stimulated the expression of the structural operon 
luxCDAB.6,7 This operon encodes the light producing luciferase enzyme.  Today, QS has 
been observed in both Gram-negative and Gram-positive bacteria though the mechanism 
of QS differs.   
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Table 1. Classification of QS autoinducer molecules 
 
Gram-positive bacteria use small cyclic peptides called autoinducer peptides 
(AIP) as signaling molecules (Table 1).3,7  The AIPs are synthesized in the cytoplasm and 
are actively transported out of the cell to interact with a two-component type extracellular 
domain of membrane bound sensor receptors.6,7  The bound AIP initiates a 
phosphorylation cascade that modulates the activity of a DNA-binding protein that 
regulates transcription of target genes.  This protein is termed a response regulator and is 
highly selective for a given peptide signal.3,6,7  This selectivity allows the bacterial 
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community to communicate efficiently.  Gram-positive bacteria can use multiple AIs and 
receptors in series or in parallel to achieve desired behaviors.  One Gram-positive 
bacteria, Staphylococcus aureus, synthesize AIPs to regulate the agr system that controls 
more than 70 genes that are known to code for virulence factors.8 
Quorum sensing in Gram-negative bacteria does not involve the use of AIPs.  In 
Gram-negative bacteria, small molecules known as acyl-homoserine-lactones (AHL/AI-
1) are used as QS signaling molecules (Table 1). QS in the V. fischeri sp. is the most 
extensively studied system to date.9-12  Two regulatory proteins, LuxI and LuxR, are 
responsible for biosynthesis of the AI and subsequent behavior of the bacteria.  The AHL 
diffuses across cell membranes and, at optimal concentrations, binds to the LuxR 
receptor, which regulates the transcription of a multitude of genes.  The Gram-negative 
bacterium Pseudomonas aeruginosa produces two AHL signals to regulate more than 
350 genes that regulate extracellular virulence factors, biofilm formation, and antibiotic 
efflux pumps.13-15 
In addition to the AIP and AI-1 systems, a universal signal molecule that allows 
inter-species communication has also been observed.3,16 This signal molecule is AI-2 
(Table 1).  When AI-2 is bound to its receptor, a phosphorylation signal cascade is 
initiated that influences the activity of a DNA-binding transcription protein.  
Although AI-1, AI-2, and AIP signaling systems have been extensively studied, 
other AI QS systems are known.  These include the epinephrine-like AI structure (AI-3) 
observed in E. coli O157:H7 that appears to regulate the formation of lesions as well as 
the isoprenoid farnesol AI signal found in the yeast Candida albicans (Table 1).16-18  The 
interest of the work herein concerns gram negative QS systems.  Many of the genes 
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transcribed by the QS molecules listed in Table 1 are those that lead to virulence, which 
includes toxin release, biofilm formation, and resistance. 
Biofilms and Resistance 
Biofilms allow bacteria to exist within a community rather than being singly 
dispersed in an environment.  Communal existence is optimal for survival and therefore 
the majority of bacteria in nature are found within biofilms.  Biofilms can have one 
species of bacteria or be a multi-species biofilm. Biofilms provide a safe environment for 
survival and symbiotic relationships so that optimal microenvironments exist.19,20  
Biofilm formation occurs when planktonic bacterial cells adhere to a surface and 
an optimal cell density is reached so that AI molecules signal QS.  The QS signaling 
pathways lead to altered gene transcription to produce an exopolysaccharide matrix.21 
This matrix envelops the micro-colony.  Inside the micro-colony, further alteration of 
genes produce a wide array of behaviors and phenotypes including attaining communal 
existence of an individual bacterial cell and up-regulation of genes encoding enzymes, 
transporters, and channels.19,22,23  The regulation of these genes produces a toxic and 
hazardous environment for foreign invaders.   
Biofilms are composed of a collection of bacterial cells that secrete the 
polysaccharide matrix.  This thick, sticky matrix acts as a shield against the host’s 
immune response by preventing access to the entire micro-colony.  Its depth limits both 
phagocytosis by neutrophils and antibiotics intervention by preventing full eradication of 
all the microbes in the community.24  Therefore, biofilms allow bacteria to become 
resistant to the host’s immune defense as well as pharmacological intervention.    Over 
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80% of bacterial infections in humans involve the formation of a biofilm.25,26 This has led 
to research into targeting QS when developing therapeutics.   
Quorum Sensing as a Drug Target 
Multi-drug resistant bacteria pose major hurdles for antibacterial therapy.  The 
ability of bacteria to resist antibiotic treatment was first observed in the late 1930s-1950s 
after the widespread dispersal of sulfonamides and penicillin.24,25 The majority of 
antibacterial compounds work by killing the bacteria as a whole.  Mutations in bacteria as 
well as improper use of drugs allow the species to survive and adapt to subsequent 
treatments, ideally becoming multi-drug resistant. Today, bacteria have the ability to gain 
resistance to every antibiotic used in treating infections.  Therefore, there is a need to 
prevent multi-drug resistance from occurring when treating bacterial infections.  One 
such option is to target the QS system used by the bacteria.  This would not kill the 
bacteria as a whole, but would prevent the transcription of genes that lead to biofilms and 
resistance.  The host’s immune response should be able to then actively target the 
infection and successfully kill the bacteria.   This approach is advantageous over 
conventional antimicrobial agents because  (1) the likelihood for rapid mutations to occur 
that develop drug resistance is low; (2) beneficial normal flora of the host is not killed; 
(3) not immediately killing the bacteria may allow the host to mount a robust immune 
response and therefore eliminate the infection without the need of bactericidal agents; and 
(4) not immediately killing the bacteria would prevent the massive release of toxic 
lipopolysaccharides associated with bacterial death, which often leads to sepsis.26  
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Figure 2. AHL-synthase substrate, AHL signal and bacterial phenotype.  Over 
70 gram negative bacterial species have been discovered to produce AHL. AHL lead to 
phenotypic behavior that is virulent to the host.  
Quorum sensing can be inhibited at one or more steps in QS pathways. In Gram-
negative bacteria, the initiator and receptor proteins (LuxI/LuxR type) are targets for 
inhibition.  One option that has been explored is to design receptor inhibitors/antagonists, 
which can bind to the AHL receptor but not elicit the subsequent biological response.26-28 
Blackwell and coworkers have reported a number of AHL receptor antagonists that 
showed biofilm inhibition activity.26-29 Most of these antagonists are designed as 
modified AHLs. The modifications include acyl chain and/or the lactone ring variations 
in the native AHL AI. Since multiple receptors are used to control QS in a cell, targeting 
the receptor to inhibit QS is very difficult.  In addition, AHL receptors bind to their 
cognate AI with nanomolar affinities and therefore it is difficult to design ligands that 
could outcompete these tight-binding native AHLs. Another option is to inhibit the 
initiator protein to stop the AI from being generated at sufficient levels required for 
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intercellular communication. This approach can prevent the biofilm from forming 
because synthesis of the AHL signal would be insufficient to initiate a QS signal cascade.  
In fact, studies involving P. aeruginosa null mutants that lack the LasI AHL synthase 
show a decrease in biofilm formation and attenuated virulence.30 Although inhibition of 
AHL synthesis is desirable to interrupt interbacterial communication, designing AHL-
synthase inhibitors are not straightforward because the mechanism of AHL synthesis is 
poorly understood. A key objective of this thesis is to address mechanistic questions on 
Burkhloderia mallei BmaI1 AHL-synthase enzyme. We believe that a deeper 
understanding of the mechanism of AHL synthesis will accelerate the discovery of QS 
inhibitors.  
AHL-synthase; BmaI1 
In Gram-negative bacteria, the AHL-synthase enzyme responsible for making 
AHL AI signal are most often members of the LuxI protein family and have sequence 
similarity.30 There have been over 70 different AHL-synthases discovered to date that 
produce specific AHL signal molecules (Fig. 2).  These bacteria are pathogens to 
humans, animals, plants, aquatic life, and more due to the LuxI/LuxR QS system. Some 
examples of AHL-synthases known that lead to virulence factor expression include V. 
fisheri LuxI AHL-synthase (aquatic pathogen), Agrobacterium tumefaciens TraI AHL-
synthase (aquatic and human pathogen), Pantoea stewartii EsaI AHL-synthase (plant 
pathogen), Pseudomonas aeruginosa LasI and RhlI AHL-synthase (human pathogen), 
and the Burkholderia mallei BmaI1 AHL-synthase (animal and human pathogen).  The 
focus of this thesis is to address mechanistic questions on an AHL-synthase protein from 
B. mallei, BmaI1.   
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B. mallei was first isolated by William Schutz and Friedrich Loffler in 1882.31,32 
B. mallei is an opportunistic, aerobic, animal, and human pathogen found in the air and 
water. B. mallei infects by lysing entry vacuoles in the host’s cell.  It gains motility once 
inside the cell and can escape from cells during immune responses and antibacterial 
defenses through use of multi-nucleated giant cells (MNCs).31 This motility and evasion 
process lets the bacteria survive in the host longer, eventually forming a micro-colony 
and becoming virulent to the host.  
Glanders disease results from a B. mallei infection.  Glanders is primarily a 
disease affecting horses, but it also affects donkeys, mules, goats, dogs, cats, and 
humans.31 Geographically, the disease is found in Africa, Asia, the Middle East, and 
Central and South America.  Animal infections are common in these areas, but human 
infections have only occurred rarely and sporadically.  Most human infections occurred 
in laboratory workers and those in direct and prolonged contact with infected, domestic 
animals. This bacterium has shown resistance to a number of antibiotics including 
aminoglycosides, polymyxins, and beta-lactams. 31,32 
Even though there is wide spread knowledge of B. mallei infections that result in 
Glanders disease, there is little known about the enzymes responsible for the AHL 
signaling.  There are multiple BmaI-BmaR QS systems responsible for virulence found in 
B. mallei including BmaI1-BmaR1, BmaI3-BmaR3, and the LuxR orphan proteins 
BmaR4 and BmaR5. These systems use different acyl-ACPs to produce AHLs for a QS 
response including octanoyl-ACP (C8ACP), 3-hydroxy-octanoyl-ACP (3-OH-C8-ACP), 
hexanoyl-ACP (C6ACP), N-3-hydroxy-hexanoyl-ACP (3-OH-C6-ACP), and N-3-
hydroxy-decanoyl-ACP (N-3-OH-C10-ACP.32,33 Because pathogenic bacteria like B. 
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mallei use AHL signals to regulate virulence genes, an understanding of the mechanism 
of signal synthesis may lead to the development of QS-targeted anti-virulence molecules.   
AHL-synthase Proposed Mechanism 
AHLs are derived from S-adenosyl-L-methionine (SAM) and acyl-acyl-carrier 
protein (acyl-ACP).  The enzymes responsible for synthesizing AHLs are LuxI family 
AHL-synthases.36,37 The proposed mechanism for synthesizing all AHLs (Fig. 3) suggests 
that a general base in the AHL-synthase active site deprotonates the SAM-amine.  The 
nucleophilic SAM-amine attacks the carbonyl center on the acyl-ACP releasing holo-
ACP.  Lactonization of the SAM intermediate produces the AHL and 
methylthioadenosine (MTA).  BmaI1’s native acyl-ACP substrate is octanoyl-ACP 
(C8ACP).  When combined with SAM and C8ACP, this enzyme produces the QS AI 
signal octanoyl-homoserine-lactone (C8HSL).33  BmaI1 is auto-regulated by the C8HSL 
signal and the BmaR1 receptor.  
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Figure 3. Proposed mechanism for AHL-synthase. The acyl-ACP chain length 
varies for each AHL-synthase.  For the AHL-synthase BmaI1, octanoyl-ACP (C8ACP) is 
the substrate and octanoyl-HSL (C8HSL) is the AHL signal. 
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AHL-synthase Substrates 
S-Adenosyl-L-Methionine (SAM) 
SAM is synthesized in the cytosol by methionine adenosyl-transferase, which 
joins L-methionine to ATP and yields SAM, pyrophosphate, and phosphate ion.33   SAM 
is primarily a methyl group donor in methylation reactions of macromolecules and small 
molecules.  It is uniquely used with AHL-synthases not as a methyl donor but to form a 
lactone ring in AHL product. 
SAM is commercially available and frequently used when studying AHL-
synthases. Commercially available samples of SAM formulations are most stable at 
acidic pH and at lower temperatures.34 The purity of SAM varies due to the degradation 
of SAM by cleavage into MTA and HSL and hydrolysis to adenine and S-(5`-
deoxyribosyl)-L-methionine. The products of this degradation are also products in the 
AHL-synthase reaction (Fig. 4).34   
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Figure 4. Chemical degradation products of SAM.  HSL and MTA are products 
of AHL-synthase and can inhibit the reaction.34 
To improve SAM stability, commercially available formulations with larger 
molecular weight salts were prepared.  It is unknown whether these SAM-salts affect 
AHL-synthase activity. SAM-salts formulations like SAM-Cl, SAM-I, and SAM-tosylate 
have various sized anionic salts that potentially can affect the activity of AHL-synthases. 
One objective of this work is to study how different formulations affect SAM substrate 
activity with AHL-synthase.  
Acyl-Acyl Carrier Protein (Acyl-ACP) 
One reason AHL-synthases are difficult to study kinetically is because acyl-ACPs 
are not commercially available.  These substrates are synthesized within the bacterial cell 
during type 2 fatty acid biosynthesis. There are two laboratory methods for preparing 
acyl-ACPs; a chemical and enzymatic method.35   
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In the chemical method for synthesizing BmaI1’s substrate octanoyl-ACP, an 
activated octanoic acid is coupled with holo-ACP to make octanoyl-ACP.  Cronan has 
shown that fatty acid acyl-ACP’s can be prepared by chemical coupling of N-acyl 
imidazole (an activated carboxylic acid) with holo-ACP in nearly quantitative yields  
(Fig. 5).35  
 
Figure 5. Chemical synthesis of acyl-ACPs.  An acylated carboxylic acid is 
activated with the addition of imidazole.  Imidazole is a good leaving group and the 
carbonyl from the activated acid can be attacked by the nucleophilic thiol in holo-ACP.  
In the enzymatic method, the enzyme Sfp from Bacillus subtilis (a 
phosphopantetheinyl transferase) converts acyl-CoA to acyl-ACP (Fig. 6).35 The 
pantethiene linker and acyl chain in the acyl-ACP is provided from the acyl-CoA.  The 
broad substrate specificity of Sfp enzyme is especially convenient in making several acyl-
ACPs from their corresponding acyl-CoAs using this method. 
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Figure 6. Enzymatic preparation of acyl-ACP. Acyl-CoA couples with apo-ACP 
by nucleophilic attack of the serine hydroxyl of apo-ACP on the phosphate bond shown.  
The phosphopantethein transferase, Sfp, is the enzyme that aids this conversion.  
Several methods have been reported in the literature for purifying apo-ACP and 
acyl-ACPs.  Among them, research groups have routinely precipitated and resuspended 
the protein. Literature suggests that the purification of apo-ACP from E. coli DK547 is 
optimal when precipitating the lysate with trichloroacetic acid and sodium deoxycholate, 
and that acyl-ACP can be successfully purified by precipitation in acetone and re-
suspendion in a Tris-HCl buffer.13,36,37 However, to the best of our knowledge, there has 
been no systematic study on how precipitation and resuspension affects ACP activity. 
When performing enzymatic studies using acyl-ACP substrates, it is necessary to obtain 
the native and therefore most active substrate.  An objective of this work is to determine 
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how precipitation and resuspendion of apo-ACP and acyl-ACP affects AHL-synthase 
activity.   
AHL-synthase Assay: DCPIP Assay 
Tipton and coworkers reported a colorimetric assay that measured the activity of 
the AHL-synthase RhlI.13 This colorimetric assay utilized UV-Vis spectroscopy and the 
chemical known as 2,6-dichlorophenolindophenol (DCPIP). DCPIP is an oxidizing agent 
that absorbs at 600 nm.  Specifically, DCPIP reduces free thiols.  One product of all 
AHL-synthase reactions is holo-ACP.  Holo-ACP contains a free thiol that can be 
oxidized by DCPIP (Fig. 7). There are two reduction sites for DCPIP, so for every 2 
molecules of holo-ACP produced, one molecule of DCPIP is reduced.  The concentration 
of thiol released as a function of time can be measured by following the dye reduction 
reaction at 600 nm. This method was optimized at pH 7.2 in MES buffer for BmaI1 and 
was utilized when measuring kinetic constants.   
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Figure 7. Proposed mechanism for BmaI1 with DCPIP.  DCPIP absorbs at 600 
nm.  Two molecules of holo-ACP reduce one molecule of DCPIP.  The concentration of 
holo-ACP released can be measured as a function of time. This work studied alternative 
substrates along with native substrates for BmaI1 using this assay.  
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AHL-synthase Structure Studies  
As mentioned previously, the crystallization of a AHL-synthase bound to 
substrate have not been successful.  Therefore, information concerning substrate active 
site binding is limited.  However, two apo AHL-synthase ribbon structures, EsaI and 
LasI, have suggested conserved regions of substrate binding sites for all AHL-synthases 
(Fig. 8).38-40  The ribbon structures for these enzymes share similarities in binding sites 
for the acyl chain in acyl-ACP, the ACP, and SAM.  The overall structure for these 
enzymes is a three-layer alpha-beta-alpha sandwich consisting of 8 helices and 9 twisted 
beta-sheets.  These structures closely resemble the acyl-CoA-N-acyl-transferase fold 
family of proteins.38  
The ACP binding site was hypothesized from mutagenesis, reporter assays, and 
structural comparison studies.  Acyl carrier protein (apo-ACP) is a 9 kD protein used in 
fatty acid biosynthesis as a way of transferring hydrophobic fatty acid chains to 
enzymatic domains so to synthesize phospholipids and other specialized products, 
including lipid A, lipoic acid, and AHLs. 41-43 Apo-ACP has a conserved four-helix 
bundle.  The fatty acid chain covalently attaches to the phosphopantetheine prosthetic 
group at the N-terminal end of the helix II in apo-ACP and is located within the 
hydrophobic interior of this bundle. Computational, crystallographic, and mutagenic 
studies implicate the acidic central helix II as a “recognition helix” for interaction with 
most of the ACP enzyme partners.44 Enzyme-ACP interactions are predominantly 
electrostatic.  Since the recognition helix (helix II) in ACP is negatively charged, a region 
of the AHL-synthase should have overall positive charge to electrostatically interact. In 
fact, there are basic residues along alpha-7 and beta-8 in AHL-synthases that form a 
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positively charged patch on the surface (see Fig. 8 for description of amino acids 
involved in ACP binding). The flexible loop in LasI and an additional helix close to SAM 
binding site in EsaI also aid in ACP binding to the enzyme. Both of these regions are 
suggested to be involved in binding of the holo-ACP portion of acyl-ACP substrate in 
this enzyme.  
 
Figure 8. Ribbon Structures for AHL-synthase. (A) LasI AHL-synthase 
indicating substrate binding sites.  ACP binding site for LasI involve residues including 
Lys150, Arg154, Arg161, His165, Lys167, and Arg172. Acyl-chain binding pocket 
resides in the V-cleft and contains the residues Trp33, Trp69, Met79, leu102, Leu122, 
Met125, Leu140, Thr142, Thre144, Val148, Met151, Met152, Ala155, Leu157, Ile178, 
and Leu188; specific for LasI. (B) EsaI AHL synthase ribbon structure with 3-oxo-
hexanoyl-ACP bound in V-cleft. 38-40 
The acyl chain binding site in AHL-synthase is a V-shaped deep cleft (beta-4 and 
beta-5 in LasI structure shown) comprised of mostly hydrophobic residues (see Fig. 8 for 
description of hydrophobic residues in LasI).  This hydrophobic domain accommodates 
the acyl side chain in the active site.38-40 For LasI, the V-cleft extends deeply because the 
natural substrate, 3-oxo-dodecanoyl-HSL, has a long acyl-chain.  The acyl-ACP in EsaI 
is 3-oxo-hexanoyl-ACP. In this enzyme, the V-cleft is filled with hydrophobic residues 
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that narrow the depth to fit the shorter acyl-chain. From these two ribbon structures, it is 
hypothesized that the V-cleft is modulated according to the acyl-ACP chain length.   
An important question to consider is whether alternative acyl-ACPs fit in the V-
cleft and turn over. Ideally, the V-cleft for LasI could fit acyl chains varying from twelve 
to two carbons in position. Likewise, the V-cleft of EsaI could fit acyl chain lengths 
varying from six to two carbons.  Interestingly, it has also been shown that RhlI can make 
hexanoyl-HSL (C6HSL), which is two carbons longer than the native butyryl-HSL 
(C4HSL). This indicates that the V-cleft in the active site can accommodate different 
substrates.  The native acyl-ACP for BmaI1 is C8ACP.  The work described in this thesis 
explores whether the V-cleft in BmaI1 can turn over shorter or longer acyl chains. I 
hypothesize that studying alternative substrates with BmaI1 can provide clues into AHL-
synthase’s selectivity for the native substrate.   
AHL Signal Specificity in Gram-negative Bacteria 
Bacterial acyl-ACPs are synthesized in vivo via type II fatty acid biosynthesis 
(Fig. 9).  This process begins when acetyl-CoA is converted to malonyl-CoA by the 
enzyme acetyl-CoA carboxylase (ACC).  Then, malonoyl-CoA couples with malonyl-
CoA:ACP transferase (FabD) to produce malonyl-ACP.  Malonyl-ACP combines with 
acyl-ACP using 3-ketoacyl-ACP synthase (FabB).  This produces 3-ketoacyl-ACP.  From 
here, a series of reductions, oxidations, and eperimizations produces the elongated acyl-
ACP.  Further elongation can continue as the acyl-ACP combines with more malonyl-
ACP.  These acyl-ACPs can be made into phospholipids, lipid A, lipoic acid, and AHLs.  
19 
 
 
Figure 9. Type II fatty acid biosynthesis.  Continued elongation cycles produce a 
large cellular pool of acyl-ACPs. 
AHL-synthase specificity ensures the correct AHL signal is produced.  During 
type II fatty acid biosynthesis, there are multiple acyl-ACPs in the cytosol.  Hoang et al. 
have shown that if β-ketoacyl ACP reductase (FabG) in fatty acid biosynthesis pathway 
is rate limiting, LasI synthesized increased amounts of short chain 3-oxo-AHLs both in 
vitro and in vivo.43 This suggests that AHL-synthases can make nonspecific AHL if 
conditions are limiting.45 However, mass spectrometry and HPLC studies of AHL-
synthases reveal one predominate AHL in each bacterial species.45 This means that AHL-
synthase must react with one acyl-ACP substrate to produce one AHL signal.  If the right 
acyl-ACP were not chosen, then AHL-synthases would make multiple AHLs and some of 
them could be inhibitory to QS.  This would result in increased noise in bacterial 
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signaling that waste cellular energy resources and lead to an inefficient signaling system 
in bacteria. 
The mechanism of tight signal specificity in generation of QS signal is an 
unsolved mystery. One possible scenario is that fatty acid biosynthesis is regulated to 
selectively produce the desired acyl-ACP substrate. However, since fatty acid 
biosynthesis is interconnected to multiple metabolic pathways, it is unlikely to serve as 
major regulatory point to control QS signal selectivity. An alternative scenario is that 
AHL-synthase enzymes effectively discriminate between native and nonspecific acyl-
ACP substrates. If this is true, AHL-synthase enzymes must be able to discriminate 
between native acyl-ACP and nonspecific acyl-ACP substrates at one or more of the 
following steps: viz., binding, catalysis and/or product release (Fig. 10). If a nonspecific 
substrate binds to AHL-synthase, the enzyme should somehow keep reaction rates with 
such substrates low enough so that nonspecific signals do not accumulate in the 
environment. How the enzyme distinguishes between native and nonspecific acyl-ACP 
substrate is not well understood. Another key objective of this thesis is to understand how 
BmaI1 recognizes its cognate C8ACP from shorter and longer chain noncognate acyl-
ACPs.  
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Figure 10. Enzymatic scheme for a bi-ter ordered mechanism.  Selectivity for 
substrates can occur at the viz., binding, catalysis or product release steps indicated.   
AHL-synthase Kinetic Mechanism 
AHL-synthase follows a bi-ter mechanism (2 substrates, 3 products). The order of 
substrates addition and product release is referred to as the kinetic mechanism. Substrates 
add to the enzyme through one of the three possibilities: a) the substrates sequentially add 
in an obligatory order, b) the substrates add sequentially in a random fashion, or c) the 
substrates add via ping-pong mechanism where the first product is released before the 
second substrate adds to the enzyme (Fig. 11). The following rules are followed while 
representing a kinetic mechanism. Enzyme forms are named beginning with ‘E’. 
Substrates are named A (first substrate to bind), B (second substrate to bind), C (third 
substrate to bind) while products are named P (first product released), Q (second product 
released), R (third product released) etc. For the RhlI enzyme, substrates add in a 
sequential manner with SAM substrate binding first to the enzyme and MTA being the 
last product to be released from the enzyme active site.13,41,46 However, it is not clear 
whether all AHL-synthase enzymes follow this mechanism and so it is important to 
determine the order of substrate binding and product release for the BmaI1 enzyme.  
C8ACP SAM Holo-ACP AHL MTA
E EA EAB EPQR EQR ER E
Binding
Catalysis
Product Release
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Figure 11. Kinetic mechanism for bi-substrate enzyme mechanism. (A) Substrates 
sequentially add in an obligatory order, (B) Substrates add sequentially in a random 
fashion, (C) Substrates add via ping-pong mechanism where the first product is released 
before the second substrate adds to the enzyme.  
Initial rates for bi-substrate enzymes displaying sequential mechanism (both 
ordered and random) as a function of substrate concentration is given by the Cleland 
equation below: 
𝑉0 = 𝑉max𝑎𝑏𝐾𝑖𝐴𝐾𝑚 𝐵 + 𝐾𝑚𝐵𝑎 +  𝐾𝑚𝐴𝑏 + 𝑎𝑏    Equation 1 
Here  is the Michaelis constant for A at saturating concentrations of B 
 is the Michaelis constant for B at saturating concentrations of A 
 is the dissociation constant for EA complex.  
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For the ping-pong mechanism, the  term in the denominator drops out in 
Equation 1. Equation 2 is representative of the initial rate for a bi-substrate enzyme 
displaying a ping-pong mechanism.  
𝑉0 = 𝑉𝑚𝑎𝑥 𝑎𝑏𝐾𝑚𝐵𝑎+ 𝐾𝑚𝐴𝑏+𝑎𝑏                       Equation 2 
These equations can be simplified into a simple Michaelis-Menten (data is interpreted 
using Michaelis-Menten kinetics) form when one of the substrate’s concentrations is held 
constant.  For instance, if Equation 1 has substrate ‘b’ at a fixed concentration and 
substrate ‘a’ at variable concentrations, then the equation reduces to the following 
Michaelis-Menten form used to describe a single-substrate enzyme reaction:  
𝑉0 =   𝑉𝑀𝑎𝑥 [𝑎]𝐾𝑚 +[𝑎]       Equation 3  
The double reciprocal of Equation 3 will adjust the equation to a linear form                    
(y = mx + b).  
1
𝑉0
= 𝐾𝑚
𝑉𝑚𝑎𝑥[𝑎] + 1𝑉𝑚𝑎𝑥                                                              Equation 4 
Equation 4 determines the terms for slope and intercept for single substrate kinetics 
𝑆𝑙𝑜𝑝𝑒 =  𝐾𝑚
𝑉𝑚𝑎𝑥
  
𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 =  1
𝑉𝑚𝑎𝑥
  
Experimental results are commonly represented in double reciprocal plots. 
Generated from Equation 1, the double reciprocal plot for a bi-substrate enzyme will have 
the linear form: 
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1
𝑉0
=  1
𝑉𝑚𝑎𝑥
 ��1 + 𝐾𝑚𝐵
𝒃
� +  1
𝑎
�𝐾𝑚
𝐴 + 𝐾𝑖𝐴 .  𝐾𝑚𝐵𝑏 ��      Equation 5 
A double reciprocal plot generated from Equation 2 will have the linear form: 
1
𝑉0
=  1
𝑉𝑚𝑎𝑥
 ��1 + 𝐾𝑚𝐵
𝒃
� +  1
𝑎
(𝐾𝑚𝐴)�        Equation 6 
The slope and intercept for random and ordered sequential mechanism at fixed 
concentration of ‘b’, using Equation 4 are described below.  
𝑆𝑙𝑜𝑝𝑒 =  �𝐾𝑚𝐴 + 𝐾𝑖𝐴. 𝐾𝑚𝐵𝑏 � � 1𝑉𝑚𝑎𝑥�    Equation 7 
𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 =  �1 +  𝐾𝑚𝐵
𝐵
� �
1
𝑉𝑚𝑎𝑥
�     Equation 8 
The slope and intercept for a ping-pong mechanism at fixed concentration of ‘b’, using 
Equation 6 are described below. 
𝑆𝑙𝑜𝑝𝑒 =  � 1
𝑉𝑚𝑎𝑥
� �
1
𝑎
.𝐾𝑚𝐴�      Equation 9 
𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 =  � 1
𝑉𝑚𝑎𝑥
� �1 + 𝐾𝑚𝐵
𝑏
�     Equation 10 
In the work described herein, BmaI1 was assayed using fixed concentration of 
one of the substrate while varying the other.  The effect of change in concentration of 
fixed substrate on the slope and intercept of a double reciprocal plot revealed if the 
BmaI1 mechanism for acyl-ACP and SAM substrates is ping-pong or random/sequential.  
The patterns of the lines from the experimental data predicted bisubstrate kinetic 
mechanisms.  Parallel line patterns are usually indicative of a ping-pong mechanism. 
Since Equation 2 for ping-pong mechanisms does not have the  term, the equation 
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for slope becomes independent of fixed substrate concentration, ‘b’. Therefore, the slope 
is unaffected upon change in ‘b’ and a parallel line pattern results (Equation 9).  
Intersecting lines (Fig. 12) indicate a sequential/random mechanism (Equation 7 and 8).  
It is important to note, however, that if the KiA is small compared to the KmA, then 
parallel lines will result for a sequential and random mechanism.  
 
Figure 12. Line-Weaver Burk Plots.  Enzyme assays are performed using fixed 
concentration of one of the substrates (B in this figure), while varying the other.  Each 
line in this plot corresponds to a specific concentration of B. As B varied between 
experiments, either the slope or intercept or both will change depending on the 
mechanism of addition of two substrates.  Parallel lines do not have slope effects, 
whereas intersecting lines show a slope effect.  If lines intersect at a point other than the 
Y-axis, then an intercept effect results. 
Thesis Objectives 
The primary objectives in this thesis are to address the following questions: 
a) Does precipitation and re-suspension affect acyl-ACP activity with BmaI1 AHL-
synthase?  
b) Does BmaI1 activity change with different SAM formulations, such as SAM-chloride 
and SAM-tosylate?  
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c) How does acyl-ACP substrate activity change with acyl chain length? How does the 
catalytic efficiency of a shorter or longer chain acyl-ACP substrate compare with native 
substrate? 
d) Does the kinetic mechanism for BmaI1 change between specific and nonspecific 
substrates? If this is true, can we get additional insight on how this enzyme discriminates 
between specific and nonspecific acyl-ACP substrate?  
This is the first study to report differences in rates and mechanism for nonspecific acyl-
ACP substrate reacting with an AHL-synthase. The BmaI1 substrate specificity study 
described in this thesis is the first step towards solving the mystery of how AHL-synthase 
enzymes achieve tight signal specificity in bacterial QS.  
 
27 
 
CHAPTER TWO: MATERIAL AND METHODS 
Materials and Equipment 
All chemicals used for these projects were purchased from Sigma Aldrich.  All 
acyl-ACPs were purchased from Life Science Resource Corp. PD10 columns were 
purchased from GE Life Sciences. All UV-Vis spectrophotometric data was obtained 
using a Thermo Scientific Evolution 260 Bio UV-Vis spectrophotometer.  All samples 
were analyzed in Fisher 1 cm path length quartz cuvettes (14-385-928C).  HPLC data 
was obtained using a Thermo Scientific Accela HPLC system along with a Thermo 
Scientific Hypersil Gold C18 reverse-phase UHPLC column (25002-054630). 
Transformation occurred using a BTX ECM 630 electroporator from Dr. Cornell’s lab at 
Boise State University. 
Transformation of BmaI1 Plasmid 
A vial containing E. coli Turner DE3 competent cells (~20 µL) was placed on ice 
along with the BmaI1 plasmid was obtained from Professor Greenberg’s laboratory at the 
University of Washington.  Electro-cuvettes were cooled for a minimum of 10 minutes at 
-20 °C.  Once the competent cells were thawed (in a sterile environment), the plasmid    
(1 µL) was added to these cells.  The ligation/plasmid mixture was transferred to the 
cooled electro-cuvettes and inserted into the electroporator.  A pulse was applied for 
transformation to occur (standard conditions were applied to the electroporator for 
transformation).  Immediately after the pulse, sterile LB broth (20 µL) was added to the 
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cuvette and this solution was transferred to an Eppendorf tube.  This was placed in a 
shaker for one hour at 37 °C, 225 RPM for growth.  The turbid solution was partitioned 
and plated onto agar plates with streptomycin antibiotic selection (100 µg/mL).  
BmaI1 Growth, Expression, and Purification 
Two liters of Luria Bertani broth with 100 µg/mL streptomycin were inoculated 
with BmaI and grown at 37 °C to an OD600 of 0.5-0.6. Expression was then induced by 
addition of 0.5 mM IPTG. Growth cultures were then cooled to 16 °C and allowed to 
express and grow overnight. Growth cultures were then centrifuged at 4,500 x g at 4 °C 
for 15 minutes to pellet cells and stored at -20 °C prior to lysis. Cell pellets were thawed 
on ice for 45 minutes prior to lysis. The cell pellet was suspended in 2 mL of B-PER 
reagent was added per liter of growth to re-suspend pellet. 20 µL of (1 mg/mL) DNase 
and RNase and 25 µL of (13 mg/750 µL IPA) phenylmethylsulfonyl fluoride (PMSF) 
were added per liter of culture. Lysate was incubated at room temperature for 15 minutes 
under gentle shaking before centrifugation at 13,000 x g for 10 minutes. Supernatant was 
collected and stored on ice prior to purification. Purification was done via Ni2+ NTA 
affinity chromatography. Ni2+ NTA column was equilibrated using 0.5M NaCl in 50 mM 
Tris/HCl, pH 7.5 (Buffer A). Supernatant was loaded onto the Ni2+ NTA column and 
washed with 10 mL of 50 mM imidazole in Buffer A. BmaI1 was eluted from the column 
using 10 mL of 300 mM imidazole in Buffer A. Presence and purity of BmaI1 was 
confirmed via SDS-PAGE analysis. Concentration was determined using UV-Vis (ε280 = 
29450 M-1cm-1). 
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Preparation of Precipitated ACP 
Transformation of the ACP DK574 with pJT94 into BL21 E. coli competent cells 
was peformed using the same conditions as the BmaI1 transformation discussed above.   
Strain DK574 with pJT94 was grown in LB broth media with 15 μg/mL 
kanamycin, 50 μg/mL streptomycin, 50 µg/mL spectinomycin, and 10 μg/mL 
chloramphenicol. Acyl carrier protein and AcpH are induced by the addition of 100 μM 
IPTG and incubation for another 3 to 4 hours. Cells were collected by centrifugation, 
which were frozen for storage at -80 °C. The cell pellets were suspended in 2 mL B-PER 
per liter of culture, 40 µL lysozyme per 1 liter of culture, 20 µL DNAse per liter of 
culture, and 60 µL PMSF per liter of culture.  This was kept at room temperature for 15-
20 minutes to lyse the cells. The lysate was cleared by centrifugation at ~13,000 x g for 
30 minutes. MgCl2 was added to 25 mM and MnSO4 was added to 1.2 mM final 
concentration. The cleared lysate was incubated at 37 °C for 4 hours to convert all acyl-
carrier protein to the apo-ACP form. Cellular protein was precipitated by the slow 
addition of isopropanol to 50% with mixing and was incubated on ice for 1 hour. The 
precipitated protein was removed by centrifugation at 10000 x g for 20 minutes. The 
supernatant was stirred with 6 mL of de-fined Whatman DE52 diaminoethyl cellulose per 
liter of culture overnight (ON). The media was packed into a column and washed with 10 
column volumes of 10 mM lithium 4-morpholineethanesulfonate (MES) pH 6.1, 0.25 M 
LiCl and eluted with 10 column volumes of 10 mM lithium MES pH 6.1, 0.5 M LiCl. 
Fractions containing pure protein indicated by SDS PAGE were pooled and precipitated 
by addition of 0.02% sodium deoxycholate and 5% trichloroacetate and incubation for 30 
minutes. The suspension was pelleted by centrifugation at 14000 x g for 30 min and apo-
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ACP was resuspended in 0.5 M Tris-HCl pH 8.0. The suspended protein was then 
desalted using PD10 column, concentrated (ε280 = 1490 M-1cm-1) using a 3 kD molecular 
weight cutoff (MCO) spin filter column, and stored at -80 °C.46  
Preparation of Unprecipitated ACP  
Strain DK574 with pJT94 was grown in LB broth media with 15 μg/mL 
kanamycin, 50 μg/mL streptomycin, 50 μg/mL spectinomycin, and 10 μg/mL 
chloramphenicol. Acyl carrier protein and AcpH are induced by addition of 100 μM 
IPTG and incubation for another 3 to 4 hours. Cells were collected by centrifugation, 
which were frozen for storage at -80 °C. The cell pellets were suspended in 2 mL B-PER 
per liter of culture, 40 µL lysozyme per 1 liter growth, 20 µL DNAse per liter growth, 
and 60 µL PMSF per liter of culture.  This was kept at RT for 15-20 minutes to lyse the 
cells. The lysate was cleared by centrifugation at ~13,000 x g for 30 minutes. MgCl2 was 
added to 25 mM and MnSO4 was added to 1.2 mM final concentration. The cleared 
lysate was incubated at 37 oC for 4 hours to convert all acyl carrier protein to the apo-
ACP form. Cellular protein was precipitated by the slow addition of isopropanol to 50% 
with mixing and was incubated on ice for 1 hour. The precipitated protein was removed 
by centrifugation at 10000 x g for 20 minutes. The supernatant was stirred with 6 mL of 
de-fined Whatman DE52 diaminoethyl cellulose per liter growth ON. The media was 
packed into a column and washed with 10 column volumes of 10 mM lithium 4-
morpholineethanesulfonate (MES) pH 6.1, 0.25 M LiCl and eluted with 10 column 
volumes of 10 mM lithium MES pH 6.1, 0.5 M LiCl. Fractions containing pure protein 
indicated by SDS PAGE were pooled and desalted using PD10 column.  This was then 
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concentrated (ε280  = 1490 M-1cm-1) using a 3 kD MCO spin filter column and stored at 
stored at -80 °C. 
Preparation of Unprecipitated acyl-ACP  
Phosphopanetheinyl transferase, Sfp from Bacillus subtilis, was used to modify 
apo-ACP with acyl-CoAs to yield acyl-ACPs. The 2 mL transferase reaction contained 
50 mM Tris-HCl pH 6.8, 10 mM magnesium chloride, 750 µM apo-ACP, 937 µM acyl-
CoA (1.25X apo-ACP), and 3 µM Sfp. Acyl-CoAs were added last.  For acyl-CoAs with 
carbon chain lengths greater than eight, precipitation occurs and stops the reaction from 
going to completion.  Therefore, the volume of C10-CoA was partitioned and added to 
the solution over 15 minute intervals.  This reaction was incubated at 37 °C and 
monitored by UHPLC for completion. The reaction time varied from 15 minutes to 2.5 
hours.  Then, ammonium sulfate at 75% saturation was added to the solution for 1 h at 4 
°C and Sfp was precipitated and collected by centrifugation (13,000 x g for 15 minutes).  
The clear acyl-ACP solution was desalted by multiple washes using a 3kD MCO spin 
filter column. The desalted acyl-ACP was concentrated using a 3kD MCO spin filter 
column and stored at -80°C.  
Preparation of Precipitated acyl-ACP 
Phosphopanetheinyl transferase, Sfp from Bacillus subtilis, was used to modify 
apo-ACP with acyl-CoAs to yield acyl-ACPs. The 2 ml transferase reaction contained 50 
mM Tris-HCl pH 6.8, 10 mM magnesium chloride, 750 µM apo-ACP, 937 µM acyl-CoA 
(1.25X apo-ACP), and 3 µM Sfp. Acyl-CoAs were added last. For acyl-CoAs with 
carbon chain lengths greater than eight like decanoyl-CoA (C10CoA) precipitation occurs 
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and stops the reaction from going to completion.  Therefore, the volume of these acyl-
CoAs were partitioned and added to the solution over 15 minute intervals.  These 
reactions were incubated at 37 °C and monitored by UHPLC for completion. The 
reaction time varied from 15 minutes to 2.5 hours.  Then, ammonium sulfate at 75% 
saturation was added to the solution for 1 h at 4 °C and Sfp was precipitated and collected 
by centrifugation (13,000 x g for 15 minutes).  Acyl-ACP was precipitated with two 
volumes of acetone overnight at -20 °C. The precipitate was collected by centrifugation 
and briefly dried. Precipitated acyl-ACP was re-suspended in 15 mL of 25 mM Tris-HCl 
pH 7.5 and desalted by washing multiple times using a 3kD MCO spin filter column. The 
desalted acyl-ACP was concentrated using a 3kD MCO spin filter column and stored at   
-80 °C. 
Acyl-ACP Separation Using UHPLC 
Using a UHPLC analytical C18 column, acyl-ACP purification was determined. 
Solvent A consisted of H2O + 0.1% TFA and solvent B consisted of acetonitrile (ACN) + 
0.1% TFA. At flow rate of 600 µL/min, a gradient of 75% A and 25% B was initiated and 
over a ten minute period changed to 25% A and 75% B. 
Electrospray Ionization Mass Spectrometry  
Molecular mass of ACP and its derivatives were determined using a Bruker maxis 
Quadrupole-Time-of-Flight (Q-TOF) mass spectrometer equipped with an Electrospray 
Ionization (ESI).  Ten microliter of samples were injected onto a Phenomenex C18 
column (100 x 2.1 mm, 2.6µ) followed by a simple linear gradient for sample desalting 
and separation. The initial eluent was 98% mobile phase A (99.9% water, 0.1% formic 
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acid) and 2% B (99.9% acetonitrile, 0.1% formic acid) for 5 min and then mobile phase B 
was increased to 50% in 25 min. LC eluent was diverted to the waste during the first five 
minutes of the gradient to eliminate salts in the sample buffer. Mass analysis was 
performed using positive ion mode with a spray voltage of 4000V. Obtained mass spectra 
were deconvoluted using Bruker Data Analysis 4.0 software tool to obtain charge state 
(N) of protein ions. To calculate the molecular mass of ACP and its derivatives, the 
measured m/z values were multiplied by corresponding N and were subtracted by the 
mass of N protons (N x 1.0079). ACP: calculated average mass - 8508.3 Da, observed 
mass - 8507.5 Da; C4ACP: calculated mass – 8916.8 Da, observed mass – 8918.2 Da; 
C6ACP: calculated mass – 8944.9 Da, observed mass – 8946.2 Da; C8ACP: calculated 
mass – 8973.0 Da, observed mass – 8974.4 Da; C10ACP: calculated mass – 9000.8 Da, 
observed mass – 9002.3. 
HPLC Method Addressing Ping-Pong Mechanistic Possibility 
The experiments were conducted with using two methods. Method 1 separates 
apo-ACP from acyl-ACPs and indicates the RT for BmaI1.  Method 1 monitors the 
appearance of holo-ACP and is ten minutes.  Method 2 separates SAM from MTA and is 
a sixty minute method that monitored the appearance of MTA.  Solvent A is NanoPure 
water + 0.1% TFA and solvent D is ACN + 0.1% TFA.   
Method 1 used a 600 µL/min flow rate and started with 75% A and 25% B.  Over 
a ten minute period the gradient changed to 25% A and 75% B.  For the C8ACP/BmaI1 
test, a 1:1 mixture of C8ACP and BmaI1 enzyme were mixed at 40 µM in 100 mM 
HEPES buffer pH 7.2. This mixture was then allowed to incubate at 37°C for 30 minutes 
and then an additional 30 minutes with two HPLC injects occurring at T30 and T60. 
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After 60 minutes, 10 µL of 12 mM SAM-Cl (sigma) was added to the reaction mixture 
and allowed to incubate for 10 minutes before being injected onto the HPLC. 
Method 2 used a 500 µL/min flow rate and started with 100% A and 0% D.  Over 
a ten minute period the gradient changed to 70% A and 30% D.  For the SAM-Cl 
(Sigma)/BmaI1 test, a mixture of SAM-Cl (Sigma) and BmaI1 were mixed at 
concentrations of 100 µM and 45 µM respectively. A control was also made with only 
100 µM SAM-Cl. The reaction and control were monitored for one hour. After no change 
between the BmaI1 containing mixture and the control, 60 µM of C8ACP was then added 
to the reaction mixture and a reaction was seen. 
DCPIP Assay for BmaI1 
The enzymatic reaction catalyzed by BmaI was monitored using a colorimetric 
assay that is sensitive to the free thiol generated upon transfer of the acyl group from 
either C8ACP or various acyl-ACPs.  A typical reaction contained 30 uM DCPIP and 100 
mM HEPES, pH 7.2.  For C8ACP determination of Km and kcat, SAM was fixed at 3 mM 
while C8ACP varied from 2-100 µM.  For determination of Km and kcat for SAM, C8-
ACP was fixed at 25-30 µM.  For generating curves with different acyl-ACP varying, 
SAM was fixed at 3 or 6 mM while the acyl-ACP concentrations varied from 2-100 µM.   
For generating curves with SAM varying, acyl-ACP was kept at 5-10X the acyl-ACP’s 
Km. SAM, acyl-ACP, buffer, and DCPIP was incubated for 25 minutes before initiating 
with enzyme to eliminate background rates.  Reactions were initiated by the addition of 
BmaI1 (200 nM for C8ACP, 560 nM C6ACP, 960 µM C10ACP and 2.86 µM C4ACP, 
and 5 µM C8CoA).  The thiol-dependent reduction of DCPIP was monitored at 600 nm  
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(ε = 21000 M-1cm-1) for no more than 800 seconds. The initial rate data was fit to 
Michaelis-Menten (Equation 3) or substrate inhibition equation using GraphPad Prism 
6.0.  All experiments were done in triplicate to check for reproducibility and to estimate 
errors. 
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CHAPTER THREE: RESULTS AND DISCUSSION 
Enzyme Purification 
BmaI1 
The appearance of small white circular colonies on the streptomycin antibiotic selected 
(100 µg/mL) agar plates confirmed that the transformation of BmaI1 into E. coli Turner 
DE3 cells using electroporation was successful. Colonies were used to inoculate large 
volumes of medium with streptomycin antibiotic selection (100 µg/mL).  The large 
culture reached OD600 = 0.5-0.8 within three hours of inoculating.  Chemical lysing using 
B-PER, DNase, RNase, and PMSF was fast and efficient in producing clear yellow lysate 
(compared to sonication).  The BmaI1 plasmid that was provided by Dr. Peter 
Greenberg’s lab contained a 6-His tag for Ni-NTA affinity chromatography purification.  
The molecular weight (MW) of BmaI1 using this sequence is 22938.1Da (Fig. 13A). It is 
expected that fractions containing BmaI1 would show banding at ~23 kD.  Analysis of 
SDS-PAGE confirmed BmaI1 was isolated from Ni-NTA chromatography at ~23 kD       
(Fig. 14). 
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Figure 13. Amino Acid Sequences for BmaI1 (A) and apo-ACP (B).  Using 
Protparam the MW for BmaI1 and apo-ACP was calculated to be 22115.2 Da and 8639.5 
Da, respectively.  Adjusting for the 6-His tag added to this sequence the MW is predicted 
to be 22938.1 Da.  
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Figure 14. SDS-PAGE of BmaI1 2L culture using Ni-NTA chromatography: 
Lane 1 (L1): EZ prestained protein ladder; Lane 2 (L2): Crude BmaI1; Lane 3 (L3): 
BmaI1 Load; Lane 4 (L4): 50 mM imidazole in Tris-HCl buffer wash of BmaI1; Lane 5-
10 (L5-L10): 200 mM imidazole in Tris-HCl buffer Elutions 1-6.  BmaI1: MW - 22938.1 
Da.  The 25 kD marker is the third line up from the bottom and the elutions in lanes 5-10 
are slightly below the 25 kD marker.  These bands are around 23 kD and were 
concentrated to 1.5 mL at 97 µM.   
Apo-ACP (Precipitated and Unprecipitated) 
The appearance of small white circular colonies on agar plates with the 
kanamycin (15 μg/mL), streptomycin (50 μg/mL), spectinomycin (50 μg/mL), and 
chloramphenicol (10 μg/mL) antibiotic selection confirmed the transformation of apo-
ACP into BL21 E. coli competent cells using electroporation was successful.  Colonies 
were used to inoculate large growths with the same antibiotic selection as the plates.  The 
culture reached OD600 = 0.5-0.8 within four hours of inoculating.  Chemical lysing using 
B-PER, DNase, RNase, lysozyme, and PMSF was fast and efficient in producing clear 
yellow lysate (compared to sonication).  All cells produce holo-ACP during fatty acid 
biosynthesis and thus when isolating apo-ACP there is always holo-ACP contamination.  
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Since these two proteins are similar in structure and molecular weight, separating one 
from the other is a laborious process.  Therefore, Dr. Peter Greenberg’s lab included an 
additional gene, ACPH (ACP-hydrolase), in the plasmid that converted holo-ACP to apo-
ACP by the addition of MgCl2 and MnSO4 to the clear lysate.  The conversion of holo-
ACP to apo-ACP produces a cloudy lysate.  ACP hydrolase was precipitated with IPA 
and gave a white solid.  Removal of ACP hydrolase with centrifugation yielded a clear 
lysate.  Anion exchange chromatography was used to successfully isolate pure fractions 
of apo-ACP from other cellular debris.   The amino acid sequence of apo-ACP is shown 
in Fig. 13B and this sequence has a MW of 8639.5 Da. It is expected that fractions 
containing apo-ACP would show banding at ~9 kD.  Analysis of SDS-PAGE confirmed 
that apo-ACP was isolated by anion exchange chromatography at ~9 kD (Fig. 15).   
 
Figure 15. SDS-PAGE of apo-ACP 2L culture using anion exchange 
chromatography: Lane 1 (L1): EZ prestained low range protein ladder; Lane 2 (L2): 
Column wash with 10 mM MES + 0.5 mM LiCl pH 6.13; Lanes 3-10 (L3-L10) contains 
elutions 1-8 using10 mM MES + 0.5M LiCl pH 6.13.  Apo-ACP: MW - 8639.5 Da.  
Apo-ACP is isolated in lanes 4-10 and were concentrated to 1.5 mL at 12 mM.  
40 
 
Substrate Synthesis 
Acyl-ACP Purification 
The syntheses of all acyl-ACPs were confirmed by HPLC (Fig. 16).  Apo-ACP 
elutes at 6.0 minutes using the Method 1 described previously.  The addition of the acyl- 
pantetheine linker (Fig. 17) and acyl chain to apo-ACP shifts the retention time (RT) for 
each substrate accordingly.   
  
Figure 16. HPLC chromatograms of apo-ACP and acyl-ACPs using Method 1.  
(A) Apo-ACP eluted at 6.0 minutes; disappearance of this peak was monitored over time 
to confirm successful synthesis of acyl-ACPs.  Contamination of holo-ACP was 
monitored by the appearance of a peak at 5.2 minutes.  All samples shown are free of 
holo-ACP.  (B) Butyryl-ACP (C4ACP) eluted at 5.5 minutes and was completed within 
15 minutes.  (C) Hexanoyl-ACP (C6ACP) eluted at 5.8 minutes and was completed 
within 15 minutes.  (D) Octanoyl-ACP (C8ACP) eluted at 6.2 minutes and was 
completed within 30 minutes.  (E) Decanoyl-ACP (C10ACP) eluted at 6.6 minutes and 
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had C10CoA partitioned over a two-hour period. After addition of all C10CoA, the 
reaction was complete within 30 minutes.   
Enzymatic synthesis of acyl-ACPs requires the acyl-CoA stock to be pure.  If the 
stock has free acid CoA, then holo-ACP will contaminate the reaction (Fig. 17).  Holo-
ACP is a product of AHL-synthase BmaI1 enzymatic reactions and can inhibit 
experimental rates.   
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Figure 17. Enzymatic synthesis of holo-ACP from free acid CoA, apo-ACP, and 
Sfp.  Free acid CoA reacts freely with apo-ACP and is converted to holo-ACP with Sfp.  
Holo-ACP is a product of AHL-synthase BmaI1 enzymatic reactions and can inhibit 
experimental rates.  The portion outlined in blue is the pantetheine linker that 
differentiates holo-ACP from apo-ACP.   
To successfully study this enzyme with acyl-ACP substrates, there cannot be 
holo-ACP present.  Using the Method 1, holo-ACP elutes at 5.2 minutes.  Each acyl-ACP 
used is free of holo-ACP and has distinct RTs from apo-ACP.   These reactions are 
monitored by the depletion of the apo-ACP peak and the growth of the corresponding 
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acyl-ACP peak. The enzyme used for this reaction is Sfp and it elutes at 3.1 minutes.  It is 
important to keep track of the final volume of the completed reaction because this volume 
is needed to assess the amount of ammonium sulfate needed to precipitate out Sfp.  Once 
the enzyme has been removed from the reaction, multiple washes to remove excess acyl-
CoA and ammonium sulfate are needed to synthesize a clean acyl-ACP substrate. These 
molecules absorb UV-Vis light at 260 nm whereas apo-ACP absorbs this light at 280 nm.   
Therefore, monitoring the reduction of the 260 nm peak during each wash determined 
when each acyl-ACP was free of contamination. 
Acyl-ACP Characterization 
The syntheses of all acyl-ACPs were successfully confirmed by MS (Fig. 18).  
The obtained mass spectra were deconvoluted using the Bruker Data Analysis 4.0 
software tool to obtain the charge state (N) of protein ions. To calculate the molecular 
mass of ACP and its derivatives, the measured m/z values were multiplied by 
corresponding N and were subtracted by the mass of N protons (N x 1.0079). ACP can 
exist in two forms where a methionine residue is oxidized and where it has been 
truncated.  Both of these forms were observed using this method.  The calculated average 
mass of ACP is 8508.3 Da and its observed mass using this method was 8507.5 Da; 
C4ACP has a calculated mass of 8916.8 D and was observed at 8918.2 Da; C6ACP has a 
calculated mass of 8944.9 Da and its mass was observed at 8946.2 Da; C8ACP has a 
calculated mass of 8973.0 Da and its mass was observed at 8974.4 Da; C10ACP has a 
calculated mass of 9000.8 Da and was observed mass at 9002.3 Da.   
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Figure 18. ESI Mass Spectra of ACP and its derivatives in positive ion modes. 
ACP: calculated average mass - 8508.3 Da, observed mass - 8507.5 Da; C4ACP: 
calculated mass – 8916.8 Da, observed mass – 8918.2 Da; C6ACP: calculated mass – 
8944.9 Da, observed mass – 8946.2 Da; C8ACP: calculated mass – 8973.0 Da, observed 
mass – 8974.4 Da; C10ACP: calculated mass – 9000.8 Da, observed mass – 9002.3 Da. 
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Effect of ACP Precipitation on Substrate Activity 
Prior studies have shown that ACP conformation changes while interacting with 
different enzyme partners, but it has not been studied whether apo-ACP precipitation and 
resuspension results in subtle conformational changes in structure.  We have found that 
the most active substrate with BmaI1 has had ACP precipitated with sodium 
deoxycholate and trichloroacetic acid and acyl-ACP not precipitated with the addition of  
acetone (Fig. 19).   
 
Figure 19. Effects of ACP precipitation on BmaI1 activity. (A) Velocity vs. [C8-
ACP]; ACP was precipitated with TCA and sodium deoxycholate and C8-ACP wasn’t 
precipitated with acetone. This preparation of substrate is the most active.  (B) Velocity 
vs. [C8-ACP]; ACP is precipitated with TCA and sodium deoxycholate and C8-ACP was 
precipitated with acetone.  This is the second most active preparation of substrate. (C) 
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Velocity vs. [C8-ACP]; ACP wasn’t precipitated and the C8-ACP wasn’t precipitated.  
This was the least active preparation of substrate.   
Table 2 shows the relative % of kcat/Km for each substrate. The kcat is a Michaelis-
Menten parameter that can be calculated as Vmax/[E] and its units are 1/seconds. It is 
referred to as the ‘turn-over’ number and it is equivalent to the amount of substrate 
converted to product in one second. kcat/Km is the specificity constant referred to as the 
catalytic efficiency.  This term explains how fast the enzyme reacts with the substrate 
once it encounters the substrate. Usually, the upper limit of kcat/Km is determined by the 
rate of diffusion because the substrate has to diffuse and collide with the enzyme and fit 
into the active site before it can be converted to product.   For BmaI1 DCPIP assays, the 
catalytic efficiency is greatest for ACP precipitated and C8ACP unprecipitated. 
Precipitating both samples causes a 3-fold decrease in efficiency and omitting the 
precipitation step for proteins causes a 6-fold decrease in the efficiency.   
Table 2.     C8ACP preparation and determination of Km, kcat, kcat /Km, curve type, 
and substrate inhibition  
Variable 
S 
Fixed 
S 
kcat 
(min-1) 
Km 
(µM) 
kcat/ Km 
(µM-1)(min-1) 
kcat/ Km 
#Relative % 
Curve Substrate 
Inhibition 
ACPP, 
C8ACPU 
SAM-
Cl 
5.8 ± 
0.6 
6 ± 1 0.96 ± 0.18 100 % Hyperbolic Yes 
ACPP, 
C8ACPP 
SAM-
Cl 
3.7 ± 
0.2 
11 ± 3 0.34 ± 0.09 35 % 
(3-fold) 
Hyperbolic No 
ACPU, 
C8ACPU 
SAM-
Cl 
4.6 ± 
0.5 
30 ± 6 0.15 ± 0.03 16 % 
(6-fold) 
Hyperbolic No 
#  kcat/ Km Relative % = [{kcat/ Km}acyl-ACP/{kcat/ Km}ACPP,C8ACPU] 
Effect of SAM Formulation on Substrate Activity 
The commerically available formulations of SAM-Cl and SAM-tosylate were 
assayed with BmaI1 and C8ACP.  Commercially available formulations of SAM are 
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known to break down into MTA and HSL, which have the potential to inhibit BmaI1 
activity.  Additionally, the anionic salts that stabalize SAM such as chloride and tosylate 
can affect the activity of BmaI1.  Tosylate is a bulky conjugated compound compared to 
chloride (Fig. 20).  The anionic salts could bind to BmaI1 and produce conformational 
changes that could inhibit the enzyme’s ability to turn over C8ACP.   
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Figure 20. SAM-chloride and SAM-tosylate structures.  All commercially 
available formulations of SAM are stored in acidic conditions.  SAM-Cl has a small 
anionic chloride while SAM-tosylate contains a larger MW salt that is conjugated.   
When testing SAM-Cl and SAM-tosylate, Km and kcat values were not 
differentiable in comparison (Fig. 21).  SAM-Cl Km is 1.8 ± 0.3 mM and SAM-tosylate is 
0.9 ± 0.2 mM.  The kcat for SAM-Cl is 5.8 ± 0.8 min-1 and for SAM-tosylate it is 6.2 ± 0.4 
min-1.  BmaI1 activity doesn’t change with different SAM formulations such as SAM-
chloride and SAM-tosylate.  This indicates that either substrates can be used with the 
DCPIP assay to study BmaI1. This is advantageous for laboratories that are restricted to 
purchasing formulations of SAM when studying AHL-synthases.  Interestingly, SAM-
tosylate at concentrations greater than 3 mM indicated decreased rates.  The IC50  of 
tosylate was tested and indicated inhibition occurring at 1 mM.     
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Figure 21. Effects of SAM formulations on BmaI1 activity.  Both assays were 
initiated with 200 nM BmaI1. A. SAM-Cl was used as the variable substrate and C8ACP 
unprecipitated was fixed at 20 µM.  Km (SAM-chloride) is 1.8 ± 0.3 mM; kcat is 5.8 ± 
0.8 min-1; kcat/Km is 3.2min-1mM.  B. SAM-tosylate was used as the variable substrate 
and C8ACP unprecipitated was fixed at 20 µM. Km (SAM-tosylate) is 0.9 ± 0.2 mM; 
kcat is 6.2 ± 0.4 min-1; kcat /Km is 6.9 min-1mM. SAM-tosylate at concentrations 
greater than 3 mM indicated decreased rates.  The IC50 of tosylate was tested and 
indicated inhibition occurring at 1 mM. 
Exploring the Kinetic Mechanism of BmaI1 
DCPIP assay of BmaI1, C8ACP, and SAM 
Plotting the double reciprocal of variable concentration of C8ACP and fixed 
concentrations of SAM-Cl displayed a series of parallel lines (Fig. 22).  Parallel line 
patterns are indicative of a ping-pong mechanism (Fig. 23).  
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Figure 22. Double Reciprocal Plot of BmaI1, C8ACP, and SAM using the DCPIP 
Assay.  These assays are accomplished using variable concentrations of C8ACP ranging 
from 0-100 µM while fixing SAM.  Five assays were completed using different 
concentrations of SAM-Cl ranging from 250-1500 µM.   The KiA of C8ACP is 125 ± 43 
nM.  Plotting the double reciprocal of the data generates a series of parallel lines.  This 
indicates the enzymatic mechanism is ping-pong.47  
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Figure 23. Ping-Pong Mechanism for bi-substrate Kinetics 
The double reciprocal Michaelis-Menten equation for a bisubstrate ping-pong 
mechanism is 
1
𝑉0
=  1
𝑉𝑚𝑎𝑥
 ��1 + 𝐾𝑚𝐵
𝒃
� +  1
𝑎
(𝐾𝑚𝐴)�    Equation 1 
The slope and intercept for a ping-pong mechanism is  
𝑆𝑙𝑜𝑝𝑒 =  � 1
𝑉𝑚𝑎𝑥
� �
1
𝑎
.𝐾𝑚𝐴�      Equation 2  
𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 =  � 1
𝑉𝑚𝑎𝑥
� �1 +  𝐾𝑚𝐵
𝑏
�     Equation 3  
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Ping-pong mechanisms slope becomes independent of fixed substrate 
concentration.  In this case, SAM-Cl was fixed while varying C8ACP. At times, parallel 
lines can result for sequential and random mechanisms.  The double reciprocal Michaelis-
Menten equation for these mechanisms is  
1
𝑉0
=  1
𝑉𝑚𝑎𝑥
 ��1 +  𝐾𝑚𝐵
𝒃
� +  1
𝑎
�𝐾𝑚
𝐴 +  𝐾𝑖𝐴 .  𝐾𝑚𝐵𝑏 ��    Equation 4 
Parallel lines for random and ordered sequential mechanisms occur when the KiA 
is small compared to the KmA.  This study obtained the KiA for C8ACP to be 125 ± 43 nM 
and the KmA for C8ACP is 6 ± 1 µM.  The KiA is much less than the KmA, which suggests 
that further experimentation is needed before deciding the mechanism is ping-pong.  
Eliminating Ping-Pong Mechanism 
A bi-substrate ping-pong mechanism involves one substrate adding to the enzyme 
and converting to product immediately (Fig. 23).  Therefore, if BmaI1 follows this 
mechanism, when incubating BmaI1 with C8ACP product release should be observed.   
Since acylation is dependent on the acyl-ACP substrate, holo-ACP is the expected 
product to be released when incubating with only C8ACP (Fig. 24A).  Lactonization is 
dependent on the substrate, SAM, and HSL and MTA are the expected products to be 
released when incubating only with SAM-Cl (Fig. 24B).   
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Figure 24. Expected Products when C8ACP is incubated with BmaI1 without 
SAM-Cl (A) and when SAM-Cl is incubated with BmaI1 without C8ACP (B).  Holo-
ACP can only be released when C8ACP is acylated in the active site of BmaI1.  When 
incubating with only SAM-Cl lactonization alone can produce HSL and MTA.   
Incubating SAM, C8ACP, and BmaI1 and injecting a sample for HPLC analysis 
showed C8ACP depletion and holo-ACP turned over (Fig. 25A).  Studying SAM-Cl 
turnover is more difficult because the commercially available SAM-Cl can break down 
into MTA.  This means that there is a starting amount of MTA existing before enzyme is 
added.  In order to observe the amount of MTA that has naturally broken down from 
SAM-Cl, the enzyme Methylthioadenosine/S-adenosylhomocysteine (MTA/SAH) 
nucleosidase (MTN) was added. MTN catalyzes the irreversible cleavage of the 
glycosidic bond in both 5'-methylthioadenosine (MTA) and S-adenosylhomocysteine 
(SAH) to adenine and the corresponding thioribose, 5'-methylthioribose and S-
ribosylhomocysteine, respectively.  When injecting 100 µM SAM-Cl with 1.6 µM MTN 
over 45 minutes, there was no significant peak area change observed. Therefore SAM 
and adenine seem to be stable under the reaction conditions (Fig. 26A and Table 3 and 4). 
When BmaI1 was added to this sample, there was no significant change in peak area for 
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SAM or adenine (Fig.26B). Adding C8ACP to this reaction showed a decrease in adenine 
peak (Fig. 26C).  Table 3 and 4 is a compilation of the quantitative data and sample 
definitions for these experiments (Fig. 26).   When incubating C8ACP and SAM 
independently with BmaI1, there was also was no change in the chromatogram, 
indicating the expected product of the ping-pong mechanism wasn’t produced (Fig. 25B).  
Therefore, the mechanism must be random or ordered sequential.    
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Figure 25. HPLC chromatogram using Method 1: (A) Chromatogram showing 40 
µM C8ACP and 40 µM BmaI1 incubated at time 30 (Blue) and the same reaction + 1.2 
mM SAM at time 90 (red). Near complete conversion of the C8ACP to holo-ACP is seen 
indicating active enzyme. C8ACP elutes at 6.15 minutes, holo-ACP at 5.2 minutes, and 
BmaI1 at 6.75 minutes. (B) Chromatogram showing 40 µM C8ACP and 40 µM BmaI1 
incubated at time 30 (Blue) and time 60 (red). There is no decrease in the C8ACP peak 
nor any holo-ACP. Method 1 used a 600 µL/min flow rate and started with 75% A and 
25% B. Solvent A is NanoPure water + 0.1% TFA and solvent D is ACN + 0.1% TFA.47  
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Figure 26. HPLC Chromatograms using Method 2: (A) Chromatogram of Control 
showing 100 µM SAM-Cl and 1.6 µM MTN at time 0 (blue) and time 45 (red). No 
significant peak area change is seen. Therefore, SAM and adenine seem to be stable in 
reaction. (B) Chromatogram of Control at time 45 (Blue) and 19. 4 µM of BmaI1 reaction 
at T60 (Red). No significant change in peak area for SAM or adenine is seen. (C) 
Chromatogram of control reaction at time 60 (Blue) and BmaI1 reaction + 60uM C8ACP 
at time 80 (Red). A significant decrease in SAM area is seen along with a significant 
increase in the adenine peak as expected. Method 2 used a 500 µL/min flow rate and 
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started with 100% A and 0% D Solvent A is NanoPure water + 0.1% TFA and solvent D 
is ACN + 0.1% TFA.47  
Table 3.     Ping-pong mechanism experiment quantitative analysis with arbitrary 
peak areas47 
 Run      
Compound 
100 µM 
SAM 
100 µM 
SAM+ 1.6 
µM MTN 
Control 
T0 
Control 
T45 
BmaI1 Rxn 
T60 
BmaI1 Rxn 
+ 60 µM 
C8ACP 
SAM-Cl 18.0271 18.7008 18.4890 18.8234 18.4155 11.7485 
MTA 2.8326 0 0 0 0 0 
Adenine       0 3.23526 3.16584 3.3975 3.16434 9.4819 
SAH 0.3673 0 0 0 0 0 
SAM/Adenine NA 5.7803 5.8401 5.5403 5.81970 1.2390 
 
Table 4. Ping-pong mechanism experiment sample definitions47 
 Control BmaI1 Reaction BmaI1 Rxn + C8-ACP 
SAM: 100 µM 100 µM 100 µM 
MTN: 1.6 µM 1.6 µM 1.6 µM 
BmaI1: 0 µM 19.4 µM 19.4 µM 
HEPES Buffer: 100 mM 100 mM 100 mM 
C8-ACP 0 µM 0 µM 60 µM 
 
Acyl-Chain Length Specificity 
To determine if BmaI1 activity changes with acyl chain length, four substrates 
(C4ACP, C6ACP, C10ACP, and C8CoA) with variable concentrations were assayed with 
SAM-Cl fixed.  Figure 27 is a compilation of the Velocity vs. [Substrate] curves 
generated using this approach.  The appropriate enzyme concentration was determined 
first by varying BmaI1 with saturating concentrations of both substrates.  Incubating 
DCPIP, SAM, acyl-ACPs, and C8CoA for 25 minutes depleted background rates.  The 
Km and kcat terms were used to determine activity.   
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Figure 27. Substrate-velocity curves for nonspecific acyl-ACP substrates reacting 
with BmaI1. Initial rate as a function of substrate concentration for 3 mM SAM chloride 
(fixed) and (A) varying C4ACP in 2 µM BmaI1 (B) varying C6ACP in 0.56 µM BmaI1 
(C) varying C10ACP in 1 µM BmaI1 and (D) varying C8CoA in 5 µM BmaI1. The rate 
curves were sigmoidal for poor substrates (C4ACP, C8CoA) and hyperbolic for C6ACP 
and C10ACP substrates. The dissociation constant for C6ACP substrate inhibition is 69 ± 
14 µM. Deviation from Michaelis-Menten behavior for C4ACP and C8CoA are 
indicative of kinetic cooperativity. Positive cooperativity (Hill slope > 1) was observed 
for both of these substrates. Acyl-ACP substrates were enzymatically synthesized from 
apo-ACP and acyl-CoA. While apo-ACP was precipitated, all acyl-ACP samples 
(C4ACP, C6ACP, and C10ACP) were prepared by omitting the acetone precipitation step 
in substrate purification. C6ACP and C10ACP substrate-velocity data was fit to substrate 
inhibition equation and Michaelis-Menten equation, respectively, while C4ACP and 
C8CoA rate data was fit to Hill equation. 
To understand if structural changes in fixed acyl-ACP substrates affected SAM 
activity, four nonspecific acyl-ACP substrates (C4ACP, C6ACP, C10ACP, and C8CoA) 
were fixed and assayed with variable concentrations of SAM-Cl.   Figure 28 is a 
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compilation of Velocity vs. [Substrate] curves generated using this approach.  The 
appropriate enzyme concentration was determined first by varying BmaI1 with saturating 
concentrations of both substrates.  Incubating DCPIP, SAM, acyl-ACPs, and C8CoA for 
25 minutes depleted background rates.   
 
Figure 28. Substrate-velocity curves for SAM. A-D) Rate curves for SAM when 
the fixed substrate was 150 µM C4ACP, 38 µM C6ACP, 36 µM C10ACP, and 522 µM 
C8CoA, respectively. The enzyme concentrations were varied from 0.5 to 5 µM 
depending on the acyl-ACP substrate used in the experiment. Substrate-velocity data for 
C6ACP was fit to Michaelis-Menten equation to determine Km and kcat. Substrates that 
produced a nonhyperbolic kinetic response were fit to Hill equation to determine 
Michaelis constant and catalytic constant. 
Table 5 is a compilation of the kinetic parameters measured using these substrates 
with DCPIP.  For each variable acyl-ACP, the Km are not all comparable.  The Km for 
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variable concentrations of C8ACP with fixed SAM-Cl is 6 ± 1 μM.  C6ACP is only two 
carbons chains shorter than C8ACP and has the most similar Km.   C10ACP is only two 
carbon chains longer and C4ACP, which is four carbons chains shorter, have the most 
drastically increased values of Km.  The data suggests that substrates with different acyl-
chain lengths from C8ACP have values of Km increased and are less active.  The kcat 
decreased for alternative substrates.  The kcat of C8ACP is 5.8 ± 0.6 min-1.  Similarly to 
the data described above, C6ACP has the most similar turn over number compared to 
C8ACP.  C10ACP is only two carbon chains longer and C4ACP, which is four carbons 
chains shorter, have the most drastically decreased values of kcat.  This data suggests that 
substrates with different acyl-chain lengths from C8ACP have values of kcat decreased 
and are less active.   Therefore, this data supports that variation in acyl-chain length for 
acyl-ACPs decreases the activity of BmaI1.   
The relative catalytic efficiency all acyl-ACPs and C8CoA were compared in 
Table 5.  C6ACP is only two carbons shorter than the natural substrate and the relative 
kcat/Km is 2.5-fold less. C10ACP is two carbons longer than C8ACP and the relative 
kcat/Km is 20-fold less than C8ACP.  C4ACP is four carbons shorter than the natural 
substrate and the relative kcat/Km   is 50-fold less than C8ACP.  C8CoA is missing the 
apo-ACP protein and the relative kcat/Km   is 5000-fold less than C8ACP.  This huge 
decrease in catalytic efficiency for C8CoA indicates that ACP binding is important for 
substrate recognition and turn over.  This data also suggests that the catalytic efficiency is 
reduced for alternative acyl-ACPs and can be the kinetic parameter determining 
selectivity. 
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Table 5. Effect of acyl-ACP substrates when SAM is fixed on BmaI1 activity 
Variable S Fixed S kcat (min-1) Km µM kcat/Km (µM
-1)(min-1) kcat/Km Relatived 
C8ACPc SAM-Cl 5.8 ± 0.6 6 ± 1        0.96 ± 0.18 1.00 
C6ACPc SAM-Cl 1.5 ± 0.1 4 ± 1        0.38 ± 0.10 0.40  
C4ACPc SAM-Cl 0.60 ± 0.05 29 ± 2      0.021 ± 0.002 0.02  
C10ACPc SAM-Cl 0.90 ± 0.10 19 ± 4      0.047 ± 0.011 0.05 
C8CoA SAM-Cl 0.11 ± 0.01 541 ± 14    0.0002 ± 0.00001 0.0002  
c apo-ACP precipitated, acyl-ACP unprecipitated 
d [{kcat/ Km}/{0.96}] 
 
Table 6 is a compilation of the kinetic parameters measured using fixed substrates 
(C4ACP, C6ACP, C10ACP, C8CoA) and varying SAM-Cl.  For each acyl-ACP, the Km 
is comparable.  The kcat, however, decreased for alternative substrates compared to 
C8ACP fixed concentrations with variable concentrations of SAM-Cl.  The kcat for fixed 
concentrations of C8ACP with variable concentrations of SAM-Cl is 5.8 ± 0.6 min-1.  
The kcat for fixed C6ACP with variable SAM-Cl is the most similar to C8ACP, followed 
by fixed C10ACP and fixed C4ACP with variable SAM-Cl.  The alternative substrates 
are less active with this observed reduction in kcat for fixed acyl-ACP and variable SAM-
Cl.  
The relative catalytic efficiency for all fixed acyl-ACPs and C8CoA were 
compared in Table 6.  C6ACP is only two carbons shorter than the natural substrate and 
the measured kcat/Km  was almost identical to C8ACP. C10ACP is two carbons longer 
than C8ACP and the relative kcat/Km is 6.3-fold less than C8ACP.  C4ACP is four carbons 
shorter than the natural substrate and the relative kcat/Km is 5.6-fold less than C8ACP.  
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C8CoA is missing the apo-ACP protein and the relative kcat/Km is 20-fold less than 
C8ACP. This data also suggests that the catalytic efficiency is reduced for alternative 
acyl-ACPs.  
Table 6.      Effect of SAM when acyl-ACP substrates are fixed on BmaI1 activity 
Variable S Fixed S kcat (min-1) Km mM kcat/ Km (mM-1)(min-1) kcat/ Km Relatived 
SAM-Cl C8ACP 5.80 ± 0.60 1.80 ± 0.50       3.22 ± 0.96 1.00 
SAM-Cl C6ACP 1.70 ± 0.10 0.54 ± 0.07       3.17 ± 0.46 0.98  
SAM-Cl C4ACP 1.10 ± 0.20 1.91 ± 0.32       0.58 ± 0.14 0.18 
SAM-Cl C10ACP 0.40 ± 0.03 0.80 ± 0.08       0.50 ± 0.06 0.16 
SAM-Cl C8CoA 0.15 ± 0.01 0.94 ± 0.08       0.16 ± 0.02 0.05 
d [{kcat/ Km}/{3.22}] 
Since structural studies have proposed a binding site for ACP with AHL-
synthases, C8CoA was also tested to determine if activity was affected, since it doesn’t 
contain the ACP protein.  When SAM was fixed, there was a 5000-fold decrease in 
catalytic efficiency compared to C8ACP.  When C8CoA was fixed, there was a 20-fold 
decrease in catalytic activity compared to C8ACP.  C8CoA assays have the most drastic 
decrease in BmaI1 activity compared to the acyl-ACPs.  This implies that binding of the 
ACP is essential for optimal activity for BmaI1.   
Good Substrates Show Hyperbolic Behavior for Both SAM and acyl-ACP and Poor 
Substrates Show Sigmoidal Behavior 
Figure 27 and 28 show the Velocity vs. [Substrate] curves generated for variable 
acyl-ACPs and C8CoA while SAM is fixed and variable SAM while acyl-ACPs and 
C8CoA is fixed.  Interestingly, many of these curves are not hyperbolic.  Table 5 and 6 
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lists the substrate curve types generated from specific conditions.  The natural substrate to 
BmaI1, C8ACP shows a hyperbolic curve when assayed with DCPIP.  C6ACP and 
C10ACP also have a hyperbolic curve when assayed with DCPIP. These two substrates 
are only 2 carbon chains different from the natural substrate.  C4ACP is four carbons 
shorter than C8ACP and this substrate shows a sigmoidal curve when assayed with 
DCPIP.  C8CoA lacks the apo-ACP protein and it too has a sigmoidal curve.  Both 
sigmoidal curves show positive cooperativity.  This data indicates that good substrates 
show hyperbolic behavior while poor substrates show sigmoidal behavior.  
Good Substrates Show Substrate Inhibition with Fixed SAM 
Figure 27 displays the Velocity vs. [Substrate] curves generated for variable acyl-
ACPs and C8CoA while SAM is fixed. Substrate inhibition is observed with the natural 
substrate to BmaI1, C8ACP as well as with C6ACP.  Inhibition is not seen with the other 
substrates.  This postulates that good substrates like C8ACP and C6ACP show inhibition 
when they are varied with fixed SAM-Cl.  The above data can be summarized as follows: 
1. Good Substrates Show Hyperbolic Behavior for both SAM and acyl-ACP 
2. Poor substrates Show Sigmoidal Behavior 
3. Good Substrates Show Inhibition with Fixed SAM 
Discussion 
One objective of the work described in this thesis was to study BmaI1 substrate 
preparation effects on activity.  Additionally, we explored the effects on BmaI1 activity 
using acyl-ACPs with variable acyl chain lengths.  Studying BmaI1 with these alternative 
substrates provided insight into the kinetic mechanism and helped to understand how this 
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enzyme discriminates between specific and nonspecific acyl-ACP substrates.    The 
BmaI1 substrate specificity study described is our first step towards understanding how 
AHL-synthase enzymes synthesize one abundant signal from the abundant acyl-ACPs 
available to achieve QS. 
Does precipitation and resuspension affect acyl-ACP activity with BmaI1 AHL-synthase? 
Apo-ACP is precipitated using TCA and sodium deoxycholate while C8ACP is 
precipitated using acetone. We were interested to check if precipitation and resuspension 
of these proteins would affect acyl-ACP activity with BmaI1 AHL-synthase. We found 
that precipitating apo-ACP and not precipitating C8ACP with acetone gave the most 
active acyl-ACP substrate.  ACP is a dynamic protein that interacts in fatty acid 
biosynthesis with multiple enzyme domains. These interactions have been shown to cause 
conformational changes in the ACP structure that are pertinent for successful synthesis of 
acyl-ACPs.42  Ribbon structures and crystallography studies have shown that AHL-
synthases have a specific position for ACP to bind in the active site (Fig. 8).38-40  It is not 
unreasonable to predict that the conformation of ACP changes during this interaction.  
This suggests a specific conformation of ACP is needed during AHL synthesis using 
AHL-synthases like BmaI1.   If preparation of apo-ACP itself causes a conformational 
change in ACP that is not native to the BmaI1 reaction, then the rate of activity could 
change. Additionally, the preparation of the acyl-ACP could induce a change in structure 
and result in a change in BmaI1 activity.   The samples that were both precipitated or 
both not precipitated had lower overall rates, which suggest the structure of ACP was 
altered from its active conformation during preparation.  
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Does BmaI1 activity change with different SAM formulations such as SAM-chloride and 
SAM-tosylate?  
AHL-synthase structure studies propose a specific binding site for SAM during 
catalysis (Fig. 8).38-40  SAM formulations like SAM-Cl and SAM-tosylate contain anionic 
salts. These salts may inhibit a chemical or enzymatic step necessary for optimal activity 
of BmaI1.  I sought to determine if the chloride or tosylate salt influenced the activity of 
BmaI1 when coupled with C8ACP. I found that commercially available formulations of 
SAM-Cl and SAM-tosylate do not affect Km or kcat measurements of BmaI1. The 
catalytic efficiency for SAM-Cl was found to be 3.2 min-1µM compared to SAM-tosylate 
at 6.9 min-1µM. This suggests that SAM-tosylate would be the better substrate to 
purchase and use when studying BmaI1.  However, the curve generated for SAM-tosylate 
showed inhibition.  This inhibition is due to the tosylate salt and lowers the overall Vmax 
observed. Therefore, to avoid complication arising from tosylate inhibition, we preferred 
to use SAM-Cl to study BmaI1.    
How does acyl-ACP substrate activity change with acyl chain length? How does the 
catalytic efficiency of a shorter or longer chain acyl-ACP substrate compare with native 
substrate?  
BmaI1 utilizes C8ACP and SAM to produce C8HSL.  The V-cleft in the active 
site accommodates the C8 acyl chain of C8ACP.  It is not unreasonable to predict that 
shorter and longer acyl chained acyl-ACPs could also ‘fit’ in this V cleft                      
(Fig. 8).  We were interested in studying the effect of variations in acyl chain length on 
BmaI1 activity. Except the C6ACP substrate, we found that all alternative acyl-ACPs and 
C8CoA had an increase in Km and a decrease in kcat compared to C8ACP.   Similar 
results were observed when the concentration of SAM was fixed with adding variable 
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concentrations of acyl-ACP, as well as when the concentration of the acyl-ACPs were 
fixed with adding variable concentrations of SAM-Cl.  The true understanding of this 
drop in activity is understood when comparing catalytic efficiencies (kcat/Km) for each 
substrate with respect to C8ACP.  
When studying the effects of alternative substrates on BmaI1 activity, it is clear 
that the catalytic efficiency is decreased compared to C8ACP.  The most comparable 
substrate to C8ACP catalytic efficiency was C6ACP, which was 4-fold less active than 
C8ACP.  C10ACP was the next more comparable substrate with a 20-fold decrease in 
catalytic efficiency.  These two substrates are only 2 carbon chains different from the 
C8ACP.  The next substrate studied was C4ACP, which had a 50-fold decrease in 
catalytic efficiency compared to C8ACP.  C4ACP is four carbon chains shorter than 
C8ACP. 
To appreciate how alternative substrates affect BmaI1 activity, it is important to 
understand how AHL-synthases interact with acyl-ACP substrates.  Unfortunately, there 
have been no enzyme-substrate crystal structures for BmaI1 to date.  It is known that 
when acyl-ACP interacts with other enzymes, the ACP portion docks to a basic residue 
patch in the partner enzyme.  Then the acyl chain is delivered by means of the 
pantetheine linker to the partner enzyme’s active site using a “switch-blade mechanism.” 
42,44   Cooperative interactions between the acyl-chain-enzyme and the ACP-enzyme site 
help lock the acyl-chain into a productive conformation. A nucleophile then attacks the 
carbonyl center of the acyl chain (much like the SAM amine in AHL-synthase reactions) 
and the reaction proceeds.  The rate of the reaction is dependent on the cooperative 
interaction and the nucleophilic attack step.  
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It is known that ACP-enzyme interactions are predominantly electrostatic due to 
the recognition helix II being negatively charged.44 AHL-synthases like BmaI1 have 
residues along alpha-7 and beta-8 that form a positively charged patch on the surface (see 
Fig. 8 for description of amino acids involved in ACP binding).  It is not unreasonable to 
predict that once the acyl chain has been delivered to BmaI1using the panthetheine linker, 
then the acyl-chain-BmaI1 and the ACP-BmaI1 complexes will undergo cooperative 
interactions.  These interactions help to position the acyl-chain into a productive 
conformation for the SAM-amine to attack the carbonyl center of the acyl-ACP at the 
acylation step. If acyl chain length variations alter the cooperative interactions and/or 
inhibit nucleophilic attack, then the activity of BmaI1 would decrease.   
When studying the effects of alternative substrates on BmaI1 activity, it is clear 
that the catalytic efficiency is decreased compared to C8ACP.  The most comparable 
substrate to C8ACP catalytic efficiency was C6ACP (Table 5).  The hexanoyl side chain 
in C6ACP is not that different from the octanoyl side chain in C8ACP.   Perhaps the 
catalytic efficiency is comparable because the thioester carbonyl of C6ACP could easily 
be locked in a productive conformation for SAM amine attack.    The decrease in 
catalytic efficiency for C6ACP can possibly be attributed to the slight increase in time it 
takes for the acyl chain interaction between enzyme and substrate to successfully lock 
and allow nucleophilic attack.  
 C10ACP was the next more comparable substrate to C8ACP (Table 5). The 
decanoyl side chain in C10ACP is only two carbons longer than the octanoyl side chain 
in C8ACP.  This increase in carbon chain length could possibly make the acyl chain 
bulge out of the V-cleft.  This puckering would restrict the flexibility of the acyl chain of 
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C10ACP and make it difficult to lock it into position for nucleophilic attack.    This 
would decrease the rate at which the product is turned over (kcat). The next substrate 
studied was C4ACP, which had a 50-fold decrease in catalytic efficiency compared to 
C8ACP.  C4ACP is four carbon chains shorter than C8ACP. It may also be that a 4-
carbon shorter acyl-chain has higher degree of freedom in the acyl-chain pocket. The 
increase in acyl-chain flexibility would make it difficult to lock the thioester carbonyl 
carbon in a productive conformation, conducive for nucleophilic attack by SAM-amine. 
This would drastically decrease the rate at which the product is turned over (kcat).   
The final substrate to study was C8CoA, which was 5000-fold less active than 
C8ACP when used as the variable substrate (Table 5).  This drop in catalytic efficiency 
suggests the rate of product turnover is negligible compared to C8ACP. C8CoA contains 
the appropriate amount of carbon chains and the pantetheine linker portion necessary for 
activity but it lacks the ACP.  A substrate without the ACP portion could not 
electrostatically bind to the positively charged residues in BmaI1.  When the substrate 
lacks ACP, the conformational changes needed to lock the carbonyl center of C8CoA into 
position for nucleophilic attack is nearly impossible.   
Does the kinetic mechanism for BmaI1 change between specific and nonspecific 
substrates? If this is true, can we get additional insight on how this enzyme discriminates 
between specific and nonspecific acyl-ACP substrate?  
We have found that the KiA for C8ACP is much less than the Km of SAM-Cl, 
which suggest BmaI1 follows an ordered sequential mechanism. We have not done any 
product inhibition experiments to confirm this mechanism. However, we have found that 
when SAM-Cl was fixed and acyl-ACP was varied the Velocity versus [Substrate] curves 
were hyperbolic for C8ACP, C6ACP, and C10ACP and sigmoidal for C4ACP and 
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C8CoA (Table 5). When acyl-ACPs were maintained at a fixed concentration and SAM-
Cl was varied, hyperbolic curves were obtained for C8ACP and C6ACP and sigmoidal 
for C4ACP, C10ACP, and C8CoA (Table 6).   
Hyperbolic curves are generated when enzymes respond linearly to changes in 
substrate concentrations when the varied substrate concentration is low. Enzymes that do 
not produce hyperbolic curves are non-cooperative and don’t follow Michaelis-Menten 
kinetics. Sigmoidal curves are generated when enzymes do not respond to changes in 
substrate concentration when the varied substrate concentration is low.  This is indicated, 
as there is no increase in reaction rate as substrate concentration is increased. Upon 
reaching a threshold concentration, a small increase in substrate concentration produces 
large changes in initial rate (inflexion region) until the reaction reaches maximal velocity 
(Vmax).   
Non-hyperbolic rate curves usually indicate a cooperative enzyme. Cooperativity 
refers to the observation that binding of the substrate or ligand at one binding site 
affects the affinity of other sites for their substrates.  Traditionally, cooperativity required 
the participation of multiple, spatially distinct binding sites that communicate with 
ligand-induced structural rearrangements and/or multimeric enzymes.48   However, 
studies have shown that cooperativity can occur in the absence of multiple binding sites 
and without macromolecular oligomerization. 48   AHL-synthases like BmaI1 have only 
been observed to have one distinct active site (V-cleft) and are monomeric.   
Cooperativity for monomeric enzymes with single ligand binding sites was first 
theorized 40 years ago.48,49,50  Only a small number of these enzymes have been 
discovered, which includes the human enzyme that is involved in glucose homeostasis, 
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glucokinase.  These monomeric cooperative systems like traditional cooperative systems 
have been attributed to slow, substrate induced alterations in enzyme structure.  These 
alterations prevent substrate binding from reaching equilibrium on the timescale of 
catalytic turnover.48,50  Therefore, the ability for alternative substrates to produce 
sigmoidal curves requires an understanding of possible enzymatic mechanisms.  The data 
summarized in the results section can fit at least two mechanistic possibilities.  
The Random Sequential Model 
The first possible mechanistic model for bisubstrate enzymes is a random 
sequential mechanism with one pathway more favored than the other (Fig. 29).  This 
model requires that the enzymatic reaction be capable of proceeding through a random 
ordered mechanism.  This model doesn’t rely on enzyme conformational heterogeneity or 
slow interconversion rates.48 This model predicts that cooperativity can be observed when 
a random sequential kinetic mechanism has a preferred pathway for substrate addition 
(Fig. 29). The disfavored pathway can be populated but contributes negligibly to the 
steady-state reaction velocity because its existence provides a mechanism where ‘non-
productive’ intermediate can accumulate.   The enzyme 3-deoxy-D-arabino-
heptulosonate-7-phosphate synthetase from Rhodomicrobium vannielli functions 
according to this model.48 
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Figure 29. Random Sequential Mechanism where the Top Pathway is Favored.  
The binding of good acyl-ACP substrate follows the top, favored pathway.  In this 
pathway, EA is the BmaI1-acyl-ACP complex. This pathway produces product at a 
higher rate than the bottom-disfavored pathway where SAM-Cl binds first. In the bottom 
pathway, EB is the BmaI1.SAM-Cl complex.     
The random sequential mechanism where one pathway is favored over the other 
can explain the two Velocity versus [Substrate] curve types observed with BmaI1.  First, 
we can predict the top pathway where acyl-ACP binds to free enzyme E is most 
favorable.  This is because the KiA for C8ACP was significantly less than the Km for 
SAM-Cl.  Substrates that produce hyperbolic curves populate the favored pathway.  This 
could be due to the BmaI1-C8ACP complex (EA) being more stable compared to the 
BmaI1.SAM-Cl (EB) complex.  The equilibrium favors the formation of EA and thus 
increased addition of acyl-ACP substrate show hyperbolic behavior.  The EB enzyme 
form can convert back to free E and the reaction favorably proceeds with EA form.  The 
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lower pathway does exist, but the more stable EA complex drives the reaction forward 
via the top pathway.  
C8ACP is the native substrate and produces a hyperbolic curve. C8ACP, 
therefore, populates the favored, more productive pathway and not the ‘less-
productive/non-productive’ pathway because cooperativity isn’t observed (Fig. 27).   
When varying acyl-ACPs, good substrates like C8ACP, C6ACP, and even C10ACP 
populate the top productive pathway even at low concentrations (Table 5).  When SAM-
Cl is varied, hyperbolic behavior is observed with C8ACP and C6ACP.    For both 
variable situations, hyperbolic curves result for these substrates because there is not 
enough free enzyme (E) to form the EB complex.  SAM-Cl then binds to the EA form to 
move the reaction favorably forward.    
Poor substrates, like C4ACP and C8CoA (whether fixing SAM or using variable 
concentrations), cannot populate the top pathway at below threshold concentrations.  This 
could be because these substrates may produce a less stable EA complex and convert 
back to free E. When SAM is in excess compared to acyl-ACP, free E converts to EB.  A 
significant portion of the enzyme would then exist in the EB form.  The EB form is in 
abundance compared to free enzyme and, so, successive addition of acyl-ACP favors 
BmaI1.SAM-Cl.acyl-ACP form.  This disfavored pathway contributes negligibly to the 
steady-state reaction velocity and a lag phase in the Velocity versus [Substrate] curve is 
observed.  This pathway can also become abortive with the accumulation of a ‘non-
productive’ complex like BmaI1.SAM-Cl-acyl-ACP.   Abortive complexes do not react 
further to produce product.  The rise in the sigmoidal curve occurs when an increase in 
acyl-ACP concentration drives BmaI1.SAM.acyl-ACP complex back to free enzyme E 
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(Table 5 and Fig. 27). Since there is an abundance of E, the chances for poor substrates to 
bind to free enzyme increases.  The top pathway will then be populated.  
Additional support for this mechanism is seen with the substrate inhibition data 
(Table 5).  The data collected suggests that good substrates show substrate inhibition only 
when using variable concentrations of acyl-ACPs.  This can be attributed to the random 
sequential model where substrate addition favors one pathway.  We discussed that good 
substrates populate the favored pathway where acyl-ACP binds first followed by SAM-
Cl.  However, good substrates can also bind to E.SAM complex and form E.SAM.acyl-
ACP populating the disfavored pathway, albeit to a smaller extent. Why is substrate 
inhibition more pronounced beyond saturation? Perhaps, there is too much acyl-ACP 
substrate around that binds to E.SAM, pushing the reaction more and more towards 
disfavored pathway. Since this pathway has either a lower turnover rate or is abortive, a 
decrease in rate is observed.  Poor substrates cannot stabilize the EA form until large 
concentrations are added.  Therefore, at low acyl-ACP concentrations, the less favored 
pathway is populated because most of the enzyme is in E.SAM form. At high 
concentrations of poor acyl-ACP substrates, the favored pathway is populated. Substrate 
inhibition is further evidence that the mechanism is random sequential where one 
pathway is favored and the other is disfavored.  
Multiple Free Enzyme Form Model 
Sigmoidal curves can result from monomeric enzymes that do not follow the 
random sequential mechanism with a favored pathway.   One such model that attests for 
monomeric cooperativity is known as the mnemonic model.  This model proposes that 
the conformation of an enzyme following product release can be different from the initial 
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enzyme state.  This requires an oscillation between two enzyme species, a low-affinity 
conformation (E*) and a high-affinity conformation (E) (Fig. 30A).  
 
Figure 30. Multiple Free Enzyme Form Models.  The mnemonic model (A), 
substrate induced enzyme transition model (B) and the ligand-induced slow transition 
model (C) require the slow interconversion between two enzyme conformations, a low-
affinity (E*) in red and a high-affinity (E) in blue. 
For the model to produce positive cooperativity (like observed with our data), the 
E* species dominates in the absence of substrate. E* to E conversion must be slow. When 
substrate bind to the less active E* form, conformational transitions occur to release 
product and to generate the high-affinity enzyme species, E.  When substrate is in excess, 
the high-affinity enzyme form, E, does not have time to ‘relax’ to the low-affinity form, 
E*. The enzyme can rapidly bind another molecule of substrate for additional rounds of 
catalysis.  This results in a hyperbolic curve.  If substrate is at low concentrations, then E 
can ‘relax’ and form E* again.  Since E* is the low affinity enzyme form, the curve will 
look sigmoidal at these low concentrations. 48,50 This model would result in sigmoidal 
curves for all substrates due to the initially slow transition from E* to E via substrate 
addition.   
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An alternative model where substrate addition converts the active enzyme ES 
complex to a less active E*S complex should also be considered (Fig. 30B; Substrate 
Induced Enzyme Transition).51  Both of these forms can convert substrate to product and 
results in the release of two enzyme forms, E and E*.  Additionally, breakdown of the 
E*S complex generates free enzyme E*.  This less active free enzyme form can react 
with substrate leading to further turnover or spontaneously revert to the more stable 
enzyme form, E.51  
An additional model that could describe monomeric cooperativity is known as the 
Ligand-Induced Slow Transition (LIST) model (Fig. 30C).48  The LIST model is similar 
to the mnemonic model in that two enzyme species exists, E* and E. These two species 
also possess different affinities for substrate.  However, the LIST model assumes that 
without substrate both enzyme forms are in a pre-existing equilibrium. The LIST model 
also assumes interconversion between these two forms occurs slower than product 
formation.  This prevents equilibration when substrate is associating.  This slow step can 
be due to isomerization or an association-dissociation process.  Both conformations are 
catalytically active, and the steady-state velocity is therefore dependent on the sum of 
these two catalytic cycle’s rates.   However, in order to support a multiple free enzyme 
model, there must be evidence that the enzyme exists in two forms. Structural and pre-
steady state kinetics are needed to verify the existence of both enzyme species.  Structural 
studies on acyl-ACP in complex with BmaI1 are in progress.   
Both random sequential and multiple free enzyme form models assume the 
existence of two enzyme forms: the more active E and less active E.* or E.SAM 
complex. The acyl-ACPs can bind to either form. Considering these models with the data 
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obtained, the addition of good substrates like C8ACP, C6ACP, and even C10ACP shift 
the equilibrium between these two enzymes species to the more active BmaI1 form. The 
more active enzyme would have a higher rate of turnover and a hyperbolic curve should 
be observed.  
Burkart and co-workers observed that when ACP binds to enzymes the acyl chain 
is released to the acyl chain pocket in the partner enzyme.52 Perhaps these poor substrates 
with nonspecific acyl chains do not fit well in the acyl chain pocket (V-cleft) of BmaI1. 
This lack of fit could revert the chain back to being sequestered into the ACP, which 
could make BmaI1.acyl-ACP complex less stable. In addition, for nonspecific substrates, 
the Enzyme.acyl-ACP complex may also be less productive. Therefore, a nonspecific 
acyl-ACP substrate could result in a less stable and less productive BmaI1.acyl-ACP 
complex thereby keeping the AHL-synthase rates low compared to the native acyl-ACP 
substrate. Our results also suggest that both binding and catalytic steps are affected when 
a nonspecific acyl-ACP substrate binds to BmaI1 AHL synthase. It is now clear that 
native acyl-ACP substrate recognition occurs at more than one step during AHL 
synthesis. 
Conclusion 
This thesis work is the first study to report differences in rates and mechanism for 
nonspecific acyl-ACP substrate reacting with an AHL-synthase.  
When studying BmaI1, we observed that the method of preparation of apo-ACP 
and the acyl-ACP is important to achieve optimum activity.  SAM-Cl and SAM-tosylate 
do not affect BmaI1 optimum activity.  Therefore, either substrate can be used to study 
AHL synthase. We found that catalytic efficiency for nonspecific acyl-ACP substrate is 
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drastically low compared to C8ACP.  This decrease in activity explains tight signal 
specificity in bacterial QS, in vivo.  The kinetic mechanism suggests a random sequential 
mechanism where one pathway (acyl-ACP binding first to the free enzyme) is favored 
over the other pathway (SAM binding first to the free enzyme).  Our data suggest that 
acyl-ACP substrate can bind to at least two enzyme forms. The formation of a stable and 
productive E.acyl-ACP complex is critical in AHL synthesis. Based on our data with 
alternative substrates, we infer that the E.acyl-ACP complex is less stable and less 
productive for nonspecific acyl-ACP substrates. Finally, acyl-ACP substrate recognition 
occurs at multiple steps in AHL synthesis.  
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